PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32420479-5	2020	Lauric acid (LA) typically increased the mRNA expression of glial-derived neurotrophic factor (Gdnf), interleukin-6 (Il6), and C-C motif chemokine 2 (Ccl2) in astrocytes.	lauric acid	0-11	glial cell derived neurotrophic factor	Homo sapiens	60-93
33214856-0	2020	Ethanol-induced CYP2E1 Expression is Reduced by Lauric Acid via PI3K Pathway in HepG2 Cells.	lauric acid	48-59	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	16-22
33214856-4	2020	Here, we aimed to evaluate the use of lauric acid as a potential antioxidant against ethanol-mediated oxidative stress by investigating its effect on CYP2E1 mRNA expression and the signalling pathway in ethanol-induced HepG2 cells.	lauric acid	38-49	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	150-156
33214856-6	2020	Ethanol induced the mRNA expression of CYP2E1 significantly, but lauric acid was able to downregulate the induced CYP2E1 expression in a dose-dependent manner.	lauric acid	65-76	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	114-120
33214856-7	2020	Similarly, Western blot analysis and densitometry analysis showed that the phosphorylated PI3K p85 (Tyr458) protein was significantly elevated in ethanol-treated HepG2 cells, but co-treatment with lauric acid repressed the activation of PI3K.	lauric acid	197-208	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	95-98
32631531-2	2020	Herein we report the synthesis and preliminary evaluation of a 11C-labeled positron emission tomography ligand based on a DAAO inhibitor, DAO-1903 (8).	lauric acid	138-141	D-amino acid oxidase	Homo sapiens	122-126
32396266-0	2020	Identification and functional characterization of CYP4V2 genetic variants exhibiting decreased activity of lauric acid metabolism.	lauric acid	107-118	cytochrome P450 family 4 subfamily V member 2	Homo sapiens	50-56
32396266-5	2020	CYP4V2 H331P and CYP4V2 G410C exhibited significant decreases in activity for lauric acid oxidation (20-30% of wild-type activity), when compared to the wildtype, which was correlated with low expression of CYP4V2 H331P and G410C substituted proteins.	lauric acid	78-89	cytochrome P450 family 4 subfamily V member 2	Homo sapiens	0-6
32396266-5	2020	CYP4V2 H331P and CYP4V2 G410C exhibited significant decreases in activity for lauric acid oxidation (20-30% of wild-type activity), when compared to the wildtype, which was correlated with low expression of CYP4V2 H331P and G410C substituted proteins.	lauric acid	78-89	cytochrome P450 family 4 subfamily V member 2	Homo sapiens	17-23
32396266-5	2020	CYP4V2 H331P and CYP4V2 G410C exhibited significant decreases in activity for lauric acid oxidation (20-30% of wild-type activity), when compared to the wildtype, which was correlated with low expression of CYP4V2 H331P and G410C substituted proteins.	lauric acid	78-89	cytochrome P450 family 4 subfamily V member 2	Homo sapiens	17-23
32396266-6	2020	The other four CYP4V2 amino variants were comparable to wild-type CYP4V2 for lauric acid metabolism.	lauric acid	77-88	cytochrome P450 family 4 subfamily V member 2	Homo sapiens	15-21
32420479-5	2020	Lauric acid (LA) typically increased the mRNA expression of glial-derived neurotrophic factor (Gdnf), interleukin-6 (Il6), and C-C motif chemokine 2 (Ccl2) in astrocytes.	lauric acid	0-11	glial cell derived neurotrophic factor	Homo sapiens	95-99
32420479-5	2020	Lauric acid (LA) typically increased the mRNA expression of glial-derived neurotrophic factor (Gdnf), interleukin-6 (Il6), and C-C motif chemokine 2 (Ccl2) in astrocytes.	lauric acid	0-11	interleukin 6	Homo sapiens	102-115
32420479-5	2020	Lauric acid (LA) typically increased the mRNA expression of glial-derived neurotrophic factor (Gdnf), interleukin-6 (Il6), and C-C motif chemokine 2 (Ccl2) in astrocytes.	lauric acid	0-11	interleukin 6	Homo sapiens	117-120
32420479-5	2020	Lauric acid (LA) typically increased the mRNA expression of glial-derived neurotrophic factor (Gdnf), interleukin-6 (Il6), and C-C motif chemokine 2 (Ccl2) in astrocytes.	lauric acid	0-11	C-C motif chemokine ligand 2	Homo sapiens	127-148
32420479-5	2020	Lauric acid (LA) typically increased the mRNA expression of glial-derived neurotrophic factor (Gdnf), interleukin-6 (Il6), and C-C motif chemokine 2 (Ccl2) in astrocytes.	lauric acid	0-11	C-C motif chemokine ligand 2	Homo sapiens	150-154
31735741-6	2019	Whereas wild-type BCR-ABL rescued the growth defect in IL-3-depleted Ba/F3 cells, mutant BCR-ABL lacking the N-terminal region failed to do so.	lauric acid	22-25	interleukin 3	Mus musculus	55-59
32276588-0	2020	CRISPR/CAS9-mediated knockout of Abi1 inhibits p185Bcr-Abl-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways.	lauric acid	55-58	abl interactor 1	Mus musculus	33-37
32276588-6	2020	RESULTS: We show here that Abi1 deficiency reduced the IL3-independent growth and SDF-1alpha-mediated chemotaxis in p185Bcr-Abl-transformed hematopoietic cells and inhibited Bcr-Abl-induced abnormal actin remodeling.	lauric acid	124-127	abl interactor 1	Mus musculus	27-31
32276588-6	2020	RESULTS: We show here that Abi1 deficiency reduced the IL3-independent growth and SDF-1alpha-mediated chemotaxis in p185Bcr-Abl-transformed hematopoietic cells and inhibited Bcr-Abl-induced abnormal actin remodeling.	lauric acid	178-181	abl interactor 1	Mus musculus	27-31
32269223-2	2020	Here, we report a H2O2/O2 self-supplying nanoagent, (MSNs@CaO2-ICG)@LA, which consists of manganese silicate (MSN)-supported calcium peroxide (CaO2) and indocyanine green (ICG) with further surface modification of phase-change material lauric acid (LA).	lauric acid	236-247	moesin	Homo sapiens	53-56
31839033-7	2019	CONCLUSION: BAX deletion can reduce the sensitivity of BCR-ABL-induced B-ALL cells to imatinib.	lauric acid	59-62	BCL2-associated X protein	Mus musculus	12-15
32879197-9	2020	However, the CYP4F substrate prostaglandin A1 (PGA1) exhibited the strongest inhibitory effect on CLA formation, while the CYP4A and CYP4B1 substrate lauric acid had no inhibitory effect.	lauric acid	150-161	cytochrome P450, family 4, subfamily b, polypeptide 1	Mus musculus	133-139
30942101-0	2019	Lauric acid induce cell death in colon cancer cells mediated by the epidermal growth factor receptor downregulation: An in silico and in vitro study.	lauric acid	0-11	epidermal growth factor receptor	Homo sapiens	68-100
30898639-2	2019	In order to increase the lipophilicity of the flavonoid and to dissolve it in SEDDS, enzymatic acylation of rutin with lauric acid was catalyzed by lipase from Candida antarctica in acetone.	lauric acid	119-130	PAN0_003d1715	Moesziomyces antarcticus	148-154
30989556-0	2019	Pro-atherogenic proteoglycanase ADAMTS-1 is down-regulated by lauric acid through PI3K and JNK signaling pathways in THP-1 derived macrophages.	lauric acid	62-73	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	32-40
30989556-0	2019	Pro-atherogenic proteoglycanase ADAMTS-1 is down-regulated by lauric acid through PI3K and JNK signaling pathways in THP-1 derived macrophages.	lauric acid	62-73	mitogen-activated protein kinase 8	Homo sapiens	91-94
30989556-4	2019	Thus, the aim of this project is to investigate the effect of lauric acid on the expression of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) genes-ADAMTS-1, ADAMTS-4, and ADAMTS-5-in macrophages.	lauric acid	62-73	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	173-181
30989556-4	2019	Thus, the aim of this project is to investigate the effect of lauric acid on the expression of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) genes-ADAMTS-1, ADAMTS-4, and ADAMTS-5-in macrophages.	lauric acid	62-73	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	183-191
30989556-4	2019	Thus, the aim of this project is to investigate the effect of lauric acid on the expression of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) genes-ADAMTS-1, ADAMTS-4, and ADAMTS-5-in macrophages.	lauric acid	62-73	ADAM metallopeptidase with thrombospondin type 1 motif 5	Homo sapiens	197-205
30989556-7	2019	Further cell signaling experiments using a panel of kinase inhibitors and phosphorylated antibodies proved that lauric acid down-regulated ADAMTS-1 by reducing the activation of PI3K and JNK at Tyr458 and Tyr185, respectively.	lauric acid	112-123	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	139-147
30989556-7	2019	Further cell signaling experiments using a panel of kinase inhibitors and phosphorylated antibodies proved that lauric acid down-regulated ADAMTS-1 by reducing the activation of PI3K and JNK at Tyr458 and Tyr185, respectively.	lauric acid	112-123	mitogen-activated protein kinase 8	Homo sapiens	187-190
30989556-8	2019	Finally, JNK1 siRNA knockdown assay confirmed that ADAMTS-1 was regulated through JNK pathway, and lauric acid interfered with this pathway to down-regulate ADAMTS-1 expression.	lauric acid	99-110	mitogen-activated protein kinase 8	Homo sapiens	9-13
30989556-8	2019	Finally, JNK1 siRNA knockdown assay confirmed that ADAMTS-1 was regulated through JNK pathway, and lauric acid interfered with this pathway to down-regulate ADAMTS-1 expression.	lauric acid	99-110	mitogen-activated protein kinase 8	Homo sapiens	9-12
30989556-8	2019	Finally, JNK1 siRNA knockdown assay confirmed that ADAMTS-1 was regulated through JNK pathway, and lauric acid interfered with this pathway to down-regulate ADAMTS-1 expression.	lauric acid	99-110	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	157-165
30989556-9	2019	Although preliminary, this present study indicates that lauric acid has the potential to stabilize atherosclerotic plaque and may prevent thrombosis by interfering with the ADAMTS-1 expression through PI3K/JNK pathways.	lauric acid	56-67	ADAM metallopeptidase with thrombospondin type 1 motif 1	Homo sapiens	173-181
30989556-9	2019	Although preliminary, this present study indicates that lauric acid has the potential to stabilize atherosclerotic plaque and may prevent thrombosis by interfering with the ADAMTS-1 expression through PI3K/JNK pathways.	lauric acid	56-67	mitogen-activated protein kinase 8	Homo sapiens	206-209
30375456-5	2018	Whole genome microarrays and RT-PCR together with the pharmacologic blocking of TGF-beta receptor type I kinase with SB431542 showed that ABL activates the TGF-beta target genes interleukin 11, proteoglycan 4, and NADPH oxidase 4.	lauric acid	138-141	transforming growth factor beta 1	Homo sapiens	80-88
30961617-0	2019	Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.	lauric acid	32-35	BCR activator of RhoGEF and GTPase	Mus musculus	28-31
30961617-0	2019	Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.	lauric acid	32-35	signal transducer and activator of transcription 5A	Mus musculus	80-85
30961617-0	2019	Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.	lauric acid	32-35	transferrin receptor	Mus musculus	86-90
30961617-4	2019	METHODS: LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation.	lauric acid	83-86	BCR activator of RhoGEF and GTPase	Mus musculus	79-82
30961617-8	2019	RESULTS: We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis.	lauric acid	88-91	BCR activator of RhoGEF and GTPase	Mus musculus	84-87
30817088-8	2019	RESULTS: We report here that ABL-conditioned titanium discs, independent of turned or rough surface, increased the expression of IL11 and NOX4.	lauric acid	29-32	interleukin 11	Mus musculus	129-133
30817088-8	2019	RESULTS: We report here that ABL-conditioned titanium discs, independent of turned or rough surface, increased the expression of IL11 and NOX4.	lauric acid	29-32	NADPH oxidase 4	Mus musculus	138-142
30817088-11	2019	Moreover, titanium discs exposed to ABL decreased alkaline phosphatase and osteopontin in ST2 cells.	lauric acid	36-39	secreted phosphoprotein 1	Mus musculus	75-86
30817088-11	2019	Moreover, titanium discs exposed to ABL decreased alkaline phosphatase and osteopontin in ST2 cells.	lauric acid	36-39	interleukin 1 receptor-like 1	Mus musculus	90-93
30598659-10	2018	Conclusion: The antitumor effect of MjTX-I is associated with its potential to induce apoptosis and cytotoxicity in Bcr-Abl positive cell lines sensitive and resistant to imatinib mesylate, indicating that MjTX-I is a promising candidate drug to upgrade the CML therapy.	lauric acid	120-123	BCR activator of RhoGEF and GTPase	Homo sapiens	116-119
30245136-4	2018	Thus, the objective of this study is to investigate the effects of ADAM10 in a sodium laurate-induced TAO rat model and elucidate underlying mechanisms.	lauric acid	79-93	ADAM metallopeptidase domain 10	Rattus norvegicus	67-73
30245136-10	2018	In conclusion, the results suggest ADAM10 alleviates symptoms of sodium laurate-induced TAO in rats via the RAGE/NF-kappaB signaling pathway and provides insight into the molecular basis and a potential therapeutic strategy for TAO.	lauric acid	65-79	ADAM metallopeptidase domain 10	Rattus norvegicus	35-41
30245136-10	2018	In conclusion, the results suggest ADAM10 alleviates symptoms of sodium laurate-induced TAO in rats via the RAGE/NF-kappaB signaling pathway and provides insight into the molecular basis and a potential therapeutic strategy for TAO.	lauric acid	65-79	advanced glycosylation end product-specific receptor	Rattus norvegicus	108-112
30063113-8	2018	In this study we evaluated the complexation of insulin glulisine, an insulin analogue administered subcutaneously or intravenously in clinical practice, with a well-known CPP modified with the MCFA lauric acid.	lauric acid	198-209	insulin	Homo sapiens	47-54
30442066-9	2019	The in vivo studies in rat ear model displayed a ~2 fold reduction in comedones count and cytokines (TNF-alpha and IL-1beta) on co-application with curcumin and lauric acid liposomal gel compared to placebo treated group.	lauric acid	161-172	interleukin 1 beta	Rattus norvegicus	115-123
31707063-5	2019	Lauric acid, a medium-chain fatty acid and the main constituent of coconut oil, increases LDL-C and HDL-C concentrations, since it plays a main role as a substrate for apolipoprotein (apo)A1 and apoB synthesis, which are the key molecules in HDL-C and LDL-C particles, respectively.Despite some findings demonstrating an increase in HDL-C, definitive long-term clinical trials are imperative to ascertain whether this effect is clinically relevant.	lauric acid	0-11	apolipoprotein A1	Homo sapiens	168-190
31707063-5	2019	Lauric acid, a medium-chain fatty acid and the main constituent of coconut oil, increases LDL-C and HDL-C concentrations, since it plays a main role as a substrate for apolipoprotein (apo)A1 and apoB synthesis, which are the key molecules in HDL-C and LDL-C particles, respectively.Despite some findings demonstrating an increase in HDL-C, definitive long-term clinical trials are imperative to ascertain whether this effect is clinically relevant.	lauric acid	0-11	apolipoprotein B	Homo sapiens	195-199
32254583-3	2018	Herein, a novel SMND of carboplatin-lauric acid nanoparticles (CBP-LA NPs) was developed for the first time to reduce GSH-mediated platinum resistance and improve the antitumor efficiency of platinum(ii).	lauric acid	36-47	CREB binding protein	Homo sapiens	63-66
30375456-5	2018	Whole genome microarrays and RT-PCR together with the pharmacologic blocking of TGF-beta receptor type I kinase with SB431542 showed that ABL activates the TGF-beta target genes interleukin 11, proteoglycan 4, and NADPH oxidase 4.	lauric acid	138-141	transforming growth factor beta 1	Homo sapiens	156-164
29852453-6	2018	In contrast, lauric acid stimulation resulted in decreased autophagy activation as shown by decreased expressions of microtubule-associated protein-1 light chain 3, autophagy-related 5, and beclin-1, which suggests decreased cellular stress.	lauric acid	13-24	beclin 1	Homo sapiens	190-198
30375456-5	2018	Whole genome microarrays and RT-PCR together with the pharmacologic blocking of TGF-beta receptor type I kinase with SB431542 showed that ABL activates the TGF-beta target genes interleukin 11, proteoglycan 4, and NADPH oxidase 4.	lauric acid	138-141	interleukin 11	Homo sapiens	178-192
30375456-5	2018	Whole genome microarrays and RT-PCR together with the pharmacologic blocking of TGF-beta receptor type I kinase with SB431542 showed that ABL activates the TGF-beta target genes interleukin 11, proteoglycan 4, and NADPH oxidase 4.	lauric acid	138-141	proteoglycan 4	Homo sapiens	194-208
30375456-5	2018	Whole genome microarrays and RT-PCR together with the pharmacologic blocking of TGF-beta receptor type I kinase with SB431542 showed that ABL activates the TGF-beta target genes interleukin 11, proteoglycan 4, and NADPH oxidase 4.	lauric acid	138-141	NADPH oxidase 4	Homo sapiens	214-229
29504668-5	2018	(2) A 6-step evaluation process (Tilt, Snap, Smile, Squint, Pull, Push) aids in ABL determination.	lauric acid	80-83	transmembrane O-mannosyltransferase targeting cadherins 3	Homo sapiens	45-50
29947014-0	2018	Lauric Acid Alleviates Neuroinflammatory Responses by Activated Microglia: Involvement of the GPR40-Dependent Pathway.	lauric acid	0-11	free fatty acid receptor 1	Homo sapiens	94-99
29877088-0	2018	Lauric Acid Accelerates Glycolytic Muscle Fiber Formation through TLR4 Signaling.	lauric acid	0-11	toll like receptor 4	Homo sapiens	66-70
29644551-5	2018	The effect of lauric acid as an active oxygen carrier was studied on epoxidation reactions where unsaturated fatty acid methyl esters were converted to epoxy fatty acid methyl esters using immobilized Candida antarctica Lipase type B as catalyst and hydrogen peroxide as oxygen donor at mild temperature and pressure conditions.	lauric acid	14-25	PAN0_003d1715	Moesziomyces antarcticus	220-226
29156154-7	2017	The study revealed that lauric acid (LA) interacts with AR and DPP-IV of polyol pathway and inhibits the activity of these enzymes.	lauric acid	24-35	aldo-keto reductase family 1 member B	Homo sapiens	56-58
29414511-5	2018	In addition we also report the 1.5 A resolution structures of human holo-RBP4 and of the protein saturated with palmitic and lauric acid and discuss the interaction of the fatty acids and retinol with the protein.	lauric acid	125-136	retinol binding protein 4	Homo sapiens	73-77
29255714-4	2017	Mouse DAO is present in the kidney, brain, and spinal cord, like DAOs in other mammals.	lauric acid	65-69	D-amino acid oxidase	Mus musculus	6-9
29247604-5	2018	The regioselective omega-hydroxylation of 1 mM DDA with near complete conversion (>99%) is achieved using a whole-cell biocatalyst co-expressing CYP153A, ferredoxin reductase and ferredoxin.	lauric acid	47-50	ferredoxin reductase	Homo sapiens	157-177
29437631-4	2018	This nonhemolytic C12-PRP is comprised of the heptapeptide sequence PRPRPRP-NH2 acylated to dodecanoic acid (C12) at the N terminus.	lauric acid	92-107	prion protein	Homo sapiens	22-25
29305929-0	2018	Cytochrome P450 4A11 inhibition assays based on characterization of lauric acid metabolites.	lauric acid	68-79	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	0-20
29305929-1	2018	This study was designed to characterize lauric acid metabolism to facilitate the establishment of cytochrome P450 4A11 (CYP4A11) inhibition assay.	lauric acid	40-51	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	98-118
29305929-1	2018	This study was designed to characterize lauric acid metabolism to facilitate the establishment of cytochrome P450 4A11 (CYP4A11) inhibition assay.	lauric acid	40-51	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	120-127
29156154-7	2017	The study revealed that lauric acid (LA) interacts with AR and DPP-IV of polyol pathway and inhibits the activity of these enzymes.	lauric acid	24-35	dipeptidyl peptidase 4	Homo sapiens	63-69
29194436-5	2017	DAO metabolises D-serine, an essential co-agonist at the N-Methyl-D-aspartic acid glutamate receptor subtype (NMDAR).	lauric acid	0-3	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	110-115
28079885-4	2017	Following an unbiased screen, elevated miRNA182-5p levels were detected in Bcr-Abl-inhibited K562 cells (CML blast crisis cell line) and in a panel of CML patients.	lauric acid	79-82	microRNA 182	Homo sapiens	39-47
28783324-7	2017	We further show that binding to the secondary binding site is specifically inhibited by mutation of VASP EVH1 domain residue Y39 to E, which mimics Abl-induced phosphorylation of Y39.	lauric acid	148-151	vasodilator stimulated phosphoprotein	Homo sapiens	100-104
28842136-9	2017	Patients with ABL-class fusions respond clinically to ABL1 tyrosine kinase inhibitors, whereas mutations activating the JAK-STAT pathway are amendable to treatment with JAK inhibitors in vitro or in preclinical models.	lauric acid	14-17	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	54-58
27871669-9	2017	Additionally, the NR2B-selective N-methyl-D-aspartate receptor antagonists ifenprodil and CP-101,606 blocked cocaine-induced habits; this was dependent on Abl family signaling in the oPFC.	lauric acid	155-158	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	18-22
28036294-0	2017	Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.	lauric acid	73-76	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
28036294-4	2017	Present studies demonstrate that double inhibition of the N- and C-terminal termini can disrupt Hsp90 chaperone function synergistically, but not antagonistically, in Bcr-Abl-positive human leukemia cells.	lauric acid	171-174	heat shock protein 90 alpha family class A member 1	Homo sapiens	96-101
27542455-3	2017	In free radical scavenging assay, the negligible decrease in EC50 of erythorbyl laurate compared to erythorbic acid manifested that C-5 selective esterification of erythorbic acid with an acyl group (lauric acid) did not reduce the inherent antioxidant activity of the donor (erythorbic acid).	lauric acid	200-211	complement C5	Homo sapiens	132-135
29018344-3	2017	Saturated fatty acids (FA) such as lauric acid (LA), are metabolized by different cytochrome P450 isoforms to omega- and (omega-1)-hydroxy products, in humans done by CYP4A11 and CYP2E1, respectively.	lauric acid	35-46	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	167-174
29018344-3	2017	Saturated fatty acids (FA) such as lauric acid (LA), are metabolized by different cytochrome P450 isoforms to omega- and (omega-1)-hydroxy products, in humans done by CYP4A11 and CYP2E1, respectively.	lauric acid	35-46	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	179-185
28873053-5	2017	We establish that species of Streptomyces secrete dodecanoic acid, which is sensed by SRB-6.	lauric acid	50-65	Serpentine receptor class beta-6	Caenorhabditis elegans	86-91
29050694-5	2017	Compelling preclinical data suggest patients harboring ABL-class rearrangements are candidates for ABL1-inhibitors, whilst alterations activating the JAK-STAT pathway may be amenable to treatment with JAK inhibitors.	lauric acid	55-58	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	99-103
28753604-0	2017	SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.	lauric acid	22-25	suppressor of cytokine signaling 1	Mus musculus	0-5
27978622-0	2017	Lauric Acid Stimulates Mammary Gland Development of Pubertal Mice through Activation of GPR84 and PI3K/Akt Signaling Pathway.	lauric acid	0-11	G protein-coupled receptor 84	Mus musculus	88-93
27507510-1	2017	The synthesis of glucose esters with palmitic acid, lauric acid and hexanoic acid using lipase enzyme was studied and their emulsion functionality in oil-in-water system were compared.	lauric acid	52-63	PAN0_003d1715	Moesziomyces antarcticus	88-94
27978622-0	2017	Lauric Acid Stimulates Mammary Gland Development of Pubertal Mice through Activation of GPR84 and PI3K/Akt Signaling Pathway.	lauric acid	0-11	thymoma viral proto-oncogene 1	Mus musculus	103-106
27422818-5	2016	This FPR2/Fpr2 agonist contains a headgroup consisting of a 2-aminooctanoic acid (Aoc) residue acylated with lauric acid (C12 fatty acid), which is linked to a peptide/peptoid repeat ((Lys-betaNphe)6-NH2).	lauric acid	109-120	formyl peptide receptor 2	Homo sapiens	5-9
27470112-2	2016	Immobilized lipase Fermase CALB 10,000 was used for the synthesis of ethyl laurate from ethanol and lauric acid.	lauric acid	100-111	calbindin 1	Homo sapiens	27-31
27679437-9	2016	The activity of key enzymes HMG- CoA reductase and lipoprotein lipase were found reduced in animals fed with lauric acid and CO.	lauric acid	109-120	lipoprotein lipase	Homo sapiens	51-69
27422818-5	2016	This FPR2/Fpr2 agonist contains a headgroup consisting of a 2-aminooctanoic acid (Aoc) residue acylated with lauric acid (C12 fatty acid), which is linked to a peptide/peptoid repeat ((Lys-betaNphe)6-NH2).	lauric acid	109-120	formyl peptide receptor 2	Homo sapiens	10-14
27422818-5	2016	This FPR2/Fpr2 agonist contains a headgroup consisting of a 2-aminooctanoic acid (Aoc) residue acylated with lauric acid (C12 fatty acid), which is linked to a peptide/peptoid repeat ((Lys-betaNphe)6-NH2).	lauric acid	122-136	formyl peptide receptor 2	Homo sapiens	5-9
27422818-5	2016	This FPR2/Fpr2 agonist contains a headgroup consisting of a 2-aminooctanoic acid (Aoc) residue acylated with lauric acid (C12 fatty acid), which is linked to a peptide/peptoid repeat ((Lys-betaNphe)6-NH2).	lauric acid	122-136	formyl peptide receptor 2	Homo sapiens	10-14
27125306-0	2016	Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.	lauric acid	26-29	growth factor receptor bound protein 2-associated protein 2	Mus musculus	0-4
27262408-3	2016	ABL-L, a semisynthetic analogue of natural sesquiterpenoid 1-O-acetylbritannilactone (ABL) isolated from Inula britannica, showed stronger suppression against three solid tumor cell lines with 4-10 fold improvement than ABL.	lauric acid	86-89	ABL proto-oncogene 2, non-receptor tyrosine kinase	Homo sapiens	0-5
26763768-4	2016	In this study, the authors modified the surface of this casted nanocomposite by grafting fibronectin derived bioactive peptides [glycine-arginine-glycine-aspartic acid-glycine (GRGDG) and lauric acid conjugated GRGDG (GRGDG-LA)] to enhance the endothelialization for using heart valves leaflets from circulating EPCs.	lauric acid	188-199	fibronectin 1	Homo sapiens	89-100
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	lauric acid	35-46	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	96-100
27115835-5	2016	Kinase profiling and further optimization resulted in eCF506, the first small molecule with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concentration to inhibit ABL.	lauric acid	187-190	v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog	Danio rerio	114-117
26863518-1	2016	The present study was conducted to determine the effects of 1-O-acetylbritannilactone (ABL), a compound extracted from Inula britannica L., on vascular endothelial growth factor (VEGF) signaling and angiogenesis in endothelial cells (ECs).	lauric acid	87-90	vascular endothelial growth factor A	Homo sapiens	143-177
26863518-1	2016	The present study was conducted to determine the effects of 1-O-acetylbritannilactone (ABL), a compound extracted from Inula britannica L., on vascular endothelial growth factor (VEGF) signaling and angiogenesis in endothelial cells (ECs).	lauric acid	87-90	vascular endothelial growth factor A	Homo sapiens	179-183
26863518-2	2016	We showed that ABL promotes VEGF-induced cell proliferation, growth, migration, and tube formation in cultured human ECs.	lauric acid	15-18	vascular endothelial growth factor A	Homo sapiens	28-32
26863518-3	2016	Furthermore, the modulatory effect of ABL on VEGF-induced Akt, MAPK p42/44, and p38 phosphorylation, as well as on upstream VEGFR-2 phosphorylation, were associated with VEGF-dependent Matrigel angiogenesis in vivo.	lauric acid	38-41	vascular endothelial growth factor A	Homo sapiens	45-49
26863518-3	2016	Furthermore, the modulatory effect of ABL on VEGF-induced Akt, MAPK p42/44, and p38 phosphorylation, as well as on upstream VEGFR-2 phosphorylation, were associated with VEGF-dependent Matrigel angiogenesis in vivo.	lauric acid	38-41	AKT serine/threonine kinase 1	Homo sapiens	58-61
26863518-3	2016	Furthermore, the modulatory effect of ABL on VEGF-induced Akt, MAPK p42/44, and p38 phosphorylation, as well as on upstream VEGFR-2 phosphorylation, were associated with VEGF-dependent Matrigel angiogenesis in vivo.	lauric acid	38-41	erythrocyte membrane protein band 4.2	Homo sapiens	68-71
26863518-3	2016	Furthermore, the modulatory effect of ABL on VEGF-induced Akt, MAPK p42/44, and p38 phosphorylation, as well as on upstream VEGFR-2 phosphorylation, were associated with VEGF-dependent Matrigel angiogenesis in vivo.	lauric acid	38-41	mitogen-activated protein kinase 14	Homo sapiens	80-83
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	kinase insert domain receptor	Homo sapiens	65-72
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	kinase insert domain receptor	Homo sapiens	103-110
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	cadherin 5	Homo sapiens	156-167
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	vascular endothelial growth factor A	Homo sapiens	65-69
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	kinase insert domain receptor	Homo sapiens	103-110
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	cadherin 5	Homo sapiens	269-280
26863518-5	2016	Finally, we demonstrated that ABL strongly reduced the levels of VEGFR-2 on the cell surface, enhanced VEGFR-2 endocytosis, which consistent with inhibited VE-cadherin, a negative regulator of VEGF signaling associated with VEGFR-2 complex formation, but did not alter VE-cadherin or VEGFR-2 expression in ECs.	lauric acid	30-33	kinase insert domain receptor	Homo sapiens	103-110
26863518-6	2016	Our results suggest that ABL may serve as a novel therapeutic intervention for various cardiovascular diseases, including chronic ischemia, by regulating VEGF signaling and modulating angiogenesis.	lauric acid	25-28	vascular endothelial growth factor A	Homo sapiens	154-158
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	lauric acid	35-46	pyruvate dehydrogenase kinase, isoenzyme 4	Mus musculus	105-109
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	lauric acid	35-46	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	148-152
27117849-7	2016	Although palmitic acid (C16:0) and lauric acid (C12:0) significantly induced expression of both UCP3 and PDK4, capric acid (C10:0) upregulated only UCP3 expression via activation of peroxisome proliferator-activated receptor-delta.	lauric acid	35-46	peroxisome proliferator activator receptor delta	Mus musculus	182-230
26496897-0	2016	Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.	lauric acid	0-11	KRAS proto-oncogene, GTPase	Homo sapiens	58-62
26496897-11	2016	This new approach may shed new light on BRAF or KRAS mutation in CRC patients for clinical trial, since lauric acid may easily be obtain from natural food, and it is supposed to be harmless to the cardiovascular system.	lauric acid	104-115	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	40-44
26496897-0	2016	Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.	lauric acid	0-11	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	63-67
26496897-11	2016	This new approach may shed new light on BRAF or KRAS mutation in CRC patients for clinical trial, since lauric acid may easily be obtain from natural food, and it is supposed to be harmless to the cardiovascular system.	lauric acid	104-115	KRAS proto-oncogene, GTPase	Homo sapiens	48-52
26496897-4	2016	The microRNA-378 (miR-378) is coexpressed with PGC-1beta and can be easily induced by fatty acid, for example lauric acid.	lauric acid	110-121	microRNA 378a	Homo sapiens	18-25
26496897-4	2016	The microRNA-378 (miR-378) is coexpressed with PGC-1beta and can be easily induced by fatty acid, for example lauric acid.	lauric acid	110-121	PPARG coactivator 1 beta	Homo sapiens	47-56
26496897-6	2016	Herein, seven CRC cell lines with confirmed mutation status were involved in two parallel experiments; directly in vitro transfected miR-378 mimics, and using lauric acid to indirectly induce the level of miR-378 in cells.	lauric acid	159-170	microRNA 378a	Homo sapiens	205-212
26496897-8	2016	Further evidence was gained by decreasing expression of MEK and ERK2 proteins after transfection with miR-378; it was similar to the indirect induction by lauric acid approach.	lauric acid	155-166	mitogen-activated protein kinase kinase 7	Homo sapiens	56-59
26496897-8	2016	Further evidence was gained by decreasing expression of MEK and ERK2 proteins after transfection with miR-378; it was similar to the indirect induction by lauric acid approach.	lauric acid	155-166	mitogen-activated protein kinase 1	Homo sapiens	64-68
26496897-8	2016	Further evidence was gained by decreasing expression of MEK and ERK2 proteins after transfection with miR-378; it was similar to the indirect induction by lauric acid approach.	lauric acid	155-166	microRNA 378a	Homo sapiens	102-109
26496897-9	2016	In conclusion, the present study demonstrated that lauric acid may efficiently induce miR-378 expression in CRC mutants, and both BRAF and a subtype of KRAS mutants presented significantly improved sensitivity to Cetuximab.	lauric acid	51-62	microRNA 378a	Homo sapiens	86-93
26102035-0	2015	1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.	lauric acid	27-30	vascular endothelial growth factor A	Homo sapiens	101-105
26887616-0	2015	[The Hsp90 inhibitor FW-04-806 suppresses Bcr/Abl-mediated growth of leukemia cells by inhibiting proliferation and inducing apoptosis].	lauric acid	46-49	heat shock protein 90 alpha family class A member 1	Homo sapiens	5-10
26581109-6	2015	A comparative functional study with Arabidopsis thaliana DGAT1 highlighted contrasting substrate specificities when the recombinant yeast was cultured in lauric acid supplemented medium.	lauric acid	154-165	membrane bound O-acyl transferase (MBOAT) family protein	Arabidopsis thaliana	57-62
26102035-0	2015	1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.	lauric acid	27-30	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	106-109
26102035-0	2015	1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.	lauric acid	27-30	protein tyrosine kinase 2	Homo sapiens	110-113
26102035-3	2015	We demonstrated that ABL dose-dependently inhibited vascular endothelial growth factor (VEGF)-induced proliferation, migration, and capillary structure formation of cultured human umbilical vascular endothelial cells (HUVECs).	lauric acid	21-24	vascular endothelial growth factor A	Homo sapiens	52-86
26102035-3	2015	We demonstrated that ABL dose-dependently inhibited vascular endothelial growth factor (VEGF)-induced proliferation, migration, and capillary structure formation of cultured human umbilical vascular endothelial cells (HUVECs).	lauric acid	21-24	vascular endothelial growth factor A	Homo sapiens	88-92
26102035-4	2015	In vivo, ABL administration suppressed VEGF-induced new vasculature formation in Matrigel plugs.	lauric acid	9-12	vascular endothelial growth factor A	Homo sapiens	39-43
26102035-5	2015	For the mechanism investigations, we found that ABL largely inhibited VEGF-mediated activation of Src kinase and focal adhesion kinase (FAK) in HUVECs.	lauric acid	48-51	vascular endothelial growth factor A	Homo sapiens	70-74
26102035-5	2015	For the mechanism investigations, we found that ABL largely inhibited VEGF-mediated activation of Src kinase and focal adhesion kinase (FAK) in HUVECs.	lauric acid	48-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	98-101
26102035-5	2015	For the mechanism investigations, we found that ABL largely inhibited VEGF-mediated activation of Src kinase and focal adhesion kinase (FAK) in HUVECs.	lauric acid	48-51	protein tyrosine kinase 2	Homo sapiens	136-139
26102035-6	2015	Furthermore, treatment of A549 NSCLC cells with ABL resulted in cell growth inhibition and Src-FAK in-activation.	lauric acid	48-51	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	91-94
26102035-6	2015	Furthermore, treatment of A549 NSCLC cells with ABL resulted in cell growth inhibition and Src-FAK in-activation.	lauric acid	48-51	protein tyrosine kinase 2	Homo sapiens	95-98
26102035-9	2015	Taken together, our findings suggest that ABL suppresses angiogenesis and lung cancer cell growth possibly via regulating the VEGFR-Src-FAK signaling.	lauric acid	42-45	kinase insert domain receptor	Homo sapiens	126-131
26102035-9	2015	Taken together, our findings suggest that ABL suppresses angiogenesis and lung cancer cell growth possibly via regulating the VEGFR-Src-FAK signaling.	lauric acid	42-45	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	132-135
26102035-9	2015	Taken together, our findings suggest that ABL suppresses angiogenesis and lung cancer cell growth possibly via regulating the VEGFR-Src-FAK signaling.	lauric acid	42-45	protein tyrosine kinase 2	Homo sapiens	136-139
25811992-7	2015	We demonstrated that ABL treatment significantly reduced neurological deficits and cerebral infarct volume by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expression in ischemic cerebral tissue and OGD-treated BV2 cells.	lauric acid	21-24	tumor necrosis factor	Mus musculus	121-148
26102025-6	2015	Our results demonstrate a contribution of CCR7 to STAP-2-dependent enhancement of BCR-ABL-mediated cell growth in Ba/F3 cells.	lauric acid	86-89	chemokine (C-C motif) receptor 7	Mus musculus	42-46
26102025-6	2015	Our results demonstrate a contribution of CCR7 to STAP-2-dependent enhancement of BCR-ABL-mediated cell growth in Ba/F3 cells.	lauric acid	86-89	signal transducing adaptor family member 2	Mus musculus	50-56
26098744-1	2015	This study selectively acylated the primary hydroxyl groups on flavonoids in antioxidant of bamboo leaves (AOB) using lauric acid with Candida antarctica lipase B in tert-amyl-alcohol.	lauric acid	118-129	lipase	Solanum tuberosum	154-160
25811992-7	2015	We demonstrated that ABL treatment significantly reduced neurological deficits and cerebral infarct volume by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expression in ischemic cerebral tissue and OGD-treated BV2 cells.	lauric acid	21-24	tumor necrosis factor	Mus musculus	150-159
25811992-7	2015	We demonstrated that ABL treatment significantly reduced neurological deficits and cerebral infarct volume by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expression in ischemic cerebral tissue and OGD-treated BV2 cells.	lauric acid	21-24	interleukin 1 beta	Mus musculus	165-182
25811992-7	2015	We demonstrated that ABL treatment significantly reduced neurological deficits and cerebral infarct volume by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expression in ischemic cerebral tissue and OGD-treated BV2 cells.	lauric acid	21-24	interleukin 1 beta	Mus musculus	184-192
25811992-8	2015	Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4).	lauric acid	118-121	tumor necrosis factor	Mus musculus	60-69
25811992-8	2015	Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4).	lauric acid	118-121	interleukin 1 beta	Mus musculus	74-82
25811992-8	2015	Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4).	lauric acid	118-121	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	163-185
25811992-8	2015	Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4).	lauric acid	118-121	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	187-196
25811992-8	2015	Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4).	lauric acid	118-121	toll-like receptor 4	Mus musculus	202-222
25811992-8	2015	Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4).	lauric acid	118-121	toll-like receptor 4	Mus musculus	224-228
25811992-9	2015	We further found that miR-155 promoted TNF-alpha and IL-1beta expression by upregulating TLR4 and downregulating the expression of suppressor of cytokine signaling 1 (SOCS1) and myeloid differentiation primary response gene 88 (MyD88), while ABL exerted an inhibitory effect on miR-155-mediated gene expression.	lauric acid	242-245	microRNA 155	Mus musculus	22-29
25811992-9	2015	We further found that miR-155 promoted TNF-alpha and IL-1beta expression by upregulating TLR4 and downregulating the expression of suppressor of cytokine signaling 1 (SOCS1) and myeloid differentiation primary response gene 88 (MyD88), while ABL exerted an inhibitory effect on miR-155-mediated gene expression.	lauric acid	242-245	tumor necrosis factor	Mus musculus	39-48
25811992-9	2015	We further found that miR-155 promoted TNF-alpha and IL-1beta expression by upregulating TLR4 and downregulating the expression of suppressor of cytokine signaling 1 (SOCS1) and myeloid differentiation primary response gene 88 (MyD88), while ABL exerted an inhibitory effect on miR-155-mediated gene expression.	lauric acid	242-245	interleukin 1 beta	Mus musculus	53-61
25138712-11	2015	Significant correlations were found in liver for CYP4A11 with lauric acid 11-/12-hydroxylation and for CYP4F2/3 and CYP4F11 with astemizole hydroxylation.	lauric acid	62-73	cytochrome P450 family 4 subfamily A member 11	Macaca fascicularis	49-56
25364244-3	2014	Here, bovine serum albumin was adsorbed onto lauric acid-stabilized SPIONs.	lauric acid	45-56	albumin	Homo sapiens	13-26
25360622-3	2014	However, the role of CDKN3 in Bcr-Abl-mediated chronic myelogenous leukemia (CML) remains unknown.	lauric acid	34-37	BCR activator of RhoGEF and GTPase	Homo sapiens	30-33
25926862-9	2014	The HMGB1 levels were higher in patients with infection during the clinical course, the HMGB1 levels in non-survivors were higher than those in survivors, and positively correlated with DAO activity, L/M ratio, the concentration of endotoxin (R = 0.484, P <0.01).	lauric acid	186-189	high mobility group box 1	Homo sapiens	88-93
25203493-0	2014	Kinetic analysis of lauric acid hydroxylation by human cytochrome P450 4A11.	lauric acid	20-31	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	55-75
25360622-4	2014	Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis.	lauric acid	59-62	cyclin dependent kinase inhibitor 3	Homo sapiens	19-24
25360622-4	2014	Here we found that CDKN3 acts as a tumor suppressor in Bcr-Abl-mediated leukemogenesis.	lauric acid	59-62	BCR activator of RhoGEF and GTPase	Homo sapiens	55-58
25046734-9	2014	Conversely, lauric acid also a saturated fatty acid was increased in response to CaMKII activation by exercise.	lauric acid	12-23	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	81-87
24909980-7	2014	Additionally, reduction of FASN expression also led to apparent decline of the relative content of decanoic acid (C10:0) and lauric acid (C12:0) in GMEC.	lauric acid	125-136	fatty acid synthase	Capra hircus	27-31
24718780-4	2014	Twelve genes were found associated with different lipid and meat quality traits, and among these stand out the considerable effect of CAST on fatness score, CGGBP1 on growth traits, HSPB1 on the percentage of lauric acid (12:0) and phospholipid docosahexaenoic acid (DHA 22:6 n - 3), RORA on the ratio of light absorption (K) to light scattering (S) (K/S), and TNFA on lightness (L*).	lauric acid	209-220	heat shock protein beta-1	Bos taurus	182-187
23831098-6	2013	Pairwise comparisons between FABP4 haplotypes for significantly associated traits showed that haplotype H3 was significantly associated with 1.04 wt% lower SFA concentration, 0.079 lower SFA:UFA ratio, 0.15 wt% lower lauric acid (12:0), and 0.27 wt% lower myristic acid (14:0) concentrations, but 1.04 wt% higher UFA and 0.91 wt% higher MUFA concentrations compared with haplotype H1 during the first 3 mo of lactation.	lauric acid	217-228	fatty acid-binding protein, adipocyte	Bos taurus	29-34
24658123-11	2014	abl-1/Abl and abi-1/Abi, which function in parallel to both CED-10/CED-1 pathways, also regulate engulfment and DTC migration.	lauric acid	6-9	Tyrosine-protein kinase;Tyrosine-protein kinase abl-1;uncharacterized protein	Caenorhabditis elegans	0-5
24404341-8	2013	These results suggest that the enzymatic activities of CYP4A11 mutants selected from directed evolution using a luminogenic P450 substrate may not demonstrate a direct correlation with the hydroxylation activities of lauric acid.	lauric acid	217-228	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	55-62
24941343-2	2014	In previous studies we found that anionic surfactants such as sodium laurate (SL) and/or sodium dodecylsulfate (SDS) exert actions on epidermal keratinocytes rather than mast cells to give rise of histamine production and skin itching through increasing the expression of the 53-kDa active form of L-histidine decarboxylase (HDC).	lauric acid	62-76	histidine decarboxylase	Homo sapiens	298-323
24941343-2	2014	In previous studies we found that anionic surfactants such as sodium laurate (SL) and/or sodium dodecylsulfate (SDS) exert actions on epidermal keratinocytes rather than mast cells to give rise of histamine production and skin itching through increasing the expression of the 53-kDa active form of L-histidine decarboxylase (HDC).	lauric acid	62-76	histidine decarboxylase	Homo sapiens	325-328
24101380-5	2013	Combined Irf8 deletion and constitutive beta-catenin activation result in progression of CML into fatal blast crisis, elevated leukemic potential of BCR-ABL-induced LICs, and Imatinib resistance.	lauric acid	153-156	interferon regulatory factor 8	Mus musculus	9-13
24101380-5	2013	Combined Irf8 deletion and constitutive beta-catenin activation result in progression of CML into fatal blast crisis, elevated leukemic potential of BCR-ABL-induced LICs, and Imatinib resistance.	lauric acid	153-156	catenin (cadherin associated protein), beta 1	Mus musculus	40-52
24098673-0	2013	Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.	lauric acid	56-59	runt related transcription factor 1	Mus musculus	25-29
24098673-0	2013	Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.	lauric acid	56-59	runt related transcription factor 1	Mus musculus	30-35
23850792-7	2013	Moreover, the accumulation of extracellular C10-carnitine in CPT2- and CACT-deficient cells suggests an extramitochondrial pathway for the oxidation of lauric acid.	lauric acid	152-163	chromosome 12 open reading frame 57	Homo sapiens	44-47
23850792-7	2013	Moreover, the accumulation of extracellular C10-carnitine in CPT2- and CACT-deficient cells suggests an extramitochondrial pathway for the oxidation of lauric acid.	lauric acid	152-163	carnitine palmitoyltransferase 2	Homo sapiens	61-65
23850792-7	2013	Moreover, the accumulation of extracellular C10-carnitine in CPT2- and CACT-deficient cells suggests an extramitochondrial pathway for the oxidation of lauric acid.	lauric acid	152-163	solute carrier family 25 member 20	Homo sapiens	71-75
23471488-2	2013	We aimed to determine whether enteric-coated pellets, releasing small amounts of lauric acid throughout the ileum and colon, could reduce glycaemic responses to meals in type 2 diabetes, associated with stimulation of GLP-1.	lauric acid	81-92	glucagon	Homo sapiens	218-223
23403193-5	2013	Haplotype H1 of SREBF1 was the most desirable to improve milk healthfulness because it was significantly associated with lower lauric (12:0) and myristic (14:0) acid concentrations compared with haplotype H3 of SREBF1, and lower lauric acid (12:0) concentration compared with haplotype H2 of SREBF1.	lauric acid	229-240	sterol regulatory element binding transcription factor 1	Homo sapiens	16-22
23069071-0	2013	High-mobility-group box protein 1A box reduces development of sodium laurate-induced thromboangiitis obliterans in rats.	lauric acid	62-76	high mobility group box 1	Rattus norvegicus	0-33
22948537-0	2013	C/EBPbeta promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.	lauric acid	23-26	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	0-9
22948537-8	2013	These results suggest that C/EBPbeta is involved in BCR-ABL-mediated myeloid expansion.	lauric acid	56-59	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	27-36
23220712-9	2013	Sodium laurate application increased the ratio of 53-kDa l-histidine decarboxylase (HDC, a key enzyme for histamine production) to 74-kDa HDC in the mouse epidermis and in a human keratinocyte culture.	lauric acid	0-14	histidine decarboxylase	Mus musculus	84-87
23220712-9	2013	Sodium laurate application increased the ratio of 53-kDa l-histidine decarboxylase (HDC, a key enzyme for histamine production) to 74-kDa HDC in the mouse epidermis and in a human keratinocyte culture.	lauric acid	0-14	histidine decarboxylase	Mus musculus	138-141
23220712-11	2013	The present results suggest that sodium laurate induced delayed scratching at an alkaline pH through the increased production of histamine in keratinocytes, which may be due to enhanced processing of 74-kDa to 53-kDa HDC.	lauric acid	33-47	histidine decarboxylase	Homo sapiens	217-220
24167354-7	2013	C-Reactive Protein (CRP) was negatively correlated with lauric acid (P = 0.048), and both CRP and CRP/Albumin ratio were negatively correlated with margaric acid (P = 0.010, P = 0.008, resp.).	lauric acid	56-67	C-reactive protein	Homo sapiens	0-18
24167354-7	2013	C-Reactive Protein (CRP) was negatively correlated with lauric acid (P = 0.048), and both CRP and CRP/Albumin ratio were negatively correlated with margaric acid (P = 0.010, P = 0.008, resp.).	lauric acid	56-67	C-reactive protein	Homo sapiens	20-23
23069071-14	2013	CONCLUSIONS: HMGB1 is involved in the inflammatory state in a model of TAO induced by sodium laurate in rats, probably via its receptor RAGE.	lauric acid	86-100	high mobility group box 1	Rattus norvegicus	13-18
23069071-14	2013	CONCLUSIONS: HMGB1 is involved in the inflammatory state in a model of TAO induced by sodium laurate in rats, probably via its receptor RAGE.	lauric acid	86-100	advanced glycosylation end product-specific receptor	Rattus norvegicus	136-140
23449492-2	2013	Topical application of sodium laurate increased hind-paw scratching, an itch-related response, 2 h after application, which was inhibited by topical post-treatment with chlorogenic acid.	lauric acid	23-37	itchy, E3 ubiquitin protein ligase	Mus musculus	72-76
23069071-3	2013	We aimed to investigate the role of HMGB1 in sodium laurate-induced TAO in rats.	lauric acid	45-59	high mobility group box 1	Rattus norvegicus	36-41
22431519-3	2012	Using BCR-ABL-induced CML mouse model, here we show that expression of the stearoyl-CoA desaturase 1 (Scd1) gene is downregulated in LSCs and that Scd1 plays a tumor-suppressive role in LSCs with no effect on the function of normal hematopoietic stem cells.	lauric acid	10-13	stearoyl-Coenzyme A desaturase 1	Mus musculus	75-100
22431519-3	2012	Using BCR-ABL-induced CML mouse model, here we show that expression of the stearoyl-CoA desaturase 1 (Scd1) gene is downregulated in LSCs and that Scd1 plays a tumor-suppressive role in LSCs with no effect on the function of normal hematopoietic stem cells.	lauric acid	10-13	stearoyl-Coenzyme A desaturase 1	Mus musculus	102-106
22431519-3	2012	Using BCR-ABL-induced CML mouse model, here we show that expression of the stearoyl-CoA desaturase 1 (Scd1) gene is downregulated in LSCs and that Scd1 plays a tumor-suppressive role in LSCs with no effect on the function of normal hematopoietic stem cells.	lauric acid	10-13	stearoyl-Coenzyme A desaturase 1	Mus musculus	147-151
22105617-8	2012	The increased expression of TNF-alpha and NF-kappaB induced by ES was also significantly decreased by ABL treatment.	lauric acid	102-105	tumor necrosis factor	Rattus norvegicus	28-37
21896918-1	2011	5-Aminoimidazole-4-carboxyamide-ribonucleoside (AICAR), a prodrug activator of AMP-activated protein kinase (AMPK), increased hepatic expression of cytochrome P450 4a10, 4a14, and 4a31 mRNAs 2-, 3-, and 4-fold, respectively, and liver microsomal lauric acid omega-hydroxylation increased 2.8-fold.	lauric acid	246-257	cytochrome P450, family 4, subfamily a, polypeptide 10	Mus musculus	148-168
22496823-4	2012	NESH/Abi-3 is a member of the Abl interactor (Abi) protein family.	lauric acid	30-33	ABI family, member 3	Rattus norvegicus	5-10
22870341-10	2012	In contrast, p210BCR-ABL-positive cells showed increased Separase proteolytic activity.	lauric acid	21-24	extra spindle pole bodies like 1, separase	Homo sapiens	57-65
23123711-8	2012	Sodium laurate application increased histamine content and the level of the active form (53 kDa) of L-histidine decarboxylase (HDC) in the mouse epidermis, but not the dermis.	lauric acid	0-14	histidine decarboxylase	Mus musculus	100-125
23123711-8	2012	Sodium laurate application increased histamine content and the level of the active form (53 kDa) of L-histidine decarboxylase (HDC) in the mouse epidermis, but not the dermis.	lauric acid	0-14	histidine decarboxylase	Mus musculus	127-130
23123711-9	2012	Furthermore, addition of sodium laurate to a human epidermal cell culture increased histamine release and HDC levels, without affecting cell viability.	lauric acid	25-39	histidine decarboxylase	Homo sapiens	106-109
21777193-5	2011	Pim kinases are critical downstream effectors of the ABL (ableson), JAK2 (janus kinase 2), and Flt-3 (FMS related tyrosine kinase 1) oncogenes and are required by them to drive tumorigenesis.	lauric acid	53-56	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-3
21777193-5	2011	Pim kinases are critical downstream effectors of the ABL (ableson), JAK2 (janus kinase 2), and Flt-3 (FMS related tyrosine kinase 1) oncogenes and are required by them to drive tumorigenesis.	lauric acid	53-56	Janus kinase 2	Homo sapiens	74-88
21811764-6	2011	We also show that ABL-induced growth inhibition is associated with the upregulation of KLF4 expression.	lauric acid	18-21	Kruppel like factor 4	Homo sapiens	87-91
21811764-7	2011	The overexpression of KLF4 by infection with pAd-KLF4 resulted in growth inhibition, with decrease in the protein levels of cyclin E and CDK4, and increase in the expression of p21, similarly to the effects of ABL.	lauric acid	210-213	Kruppel like factor 4	Homo sapiens	22-26
21811764-8	2011	Conversely, knockdown of KLF4 using a specific siRNA impaired the ABL-induced growth inhibition in HT-29 cells.	lauric acid	66-69	Kruppel like factor 4	Homo sapiens	25-29
21811764-9	2011	These results suggest that KLF4 as an important cellular target of ABL mediates the growth inhibition of HT-29 cells induced by ABL via upregulation of p21 expression.	lauric acid	67-70	Kruppel like factor 4	Homo sapiens	27-31
21811764-9	2011	These results suggest that KLF4 as an important cellular target of ABL mediates the growth inhibition of HT-29 cells induced by ABL via upregulation of p21 expression.	lauric acid	67-70	H3 histone pseudogene 16	Homo sapiens	152-155
21811764-9	2011	These results suggest that KLF4 as an important cellular target of ABL mediates the growth inhibition of HT-29 cells induced by ABL via upregulation of p21 expression.	lauric acid	128-131	Kruppel like factor 4	Homo sapiens	27-31
21811764-9	2011	These results suggest that KLF4 as an important cellular target of ABL mediates the growth inhibition of HT-29 cells induced by ABL via upregulation of p21 expression.	lauric acid	128-131	H3 histone pseudogene 16	Homo sapiens	152-155
21639134-2	2011	We recently reported a fluorescence polarization-activity-based protein profiling (fluopol-ABPP) high-throughput screen for PME-1 that uncovered a remarkably potent and selective class of aza-beta-lactam (ABL) PME-1 inhibitors.	lauric acid	205-208	amyloid beta precursor protein	Homo sapiens	91-95
21768400-3	2011	Previously, we found that alloreactive T cell targeting of GVL-sensitive bcr-abl-induced mouse CP-CML (mCP-CML) required TCR-MHC interactions and that multiple and redundant killing mechanisms were in play.	lauric acid	77-80	complement component (3b/4b) receptor 1-like	Mus musculus	103-106
21639134-2	2011	We recently reported a fluorescence polarization-activity-based protein profiling (fluopol-ABPP) high-throughput screen for PME-1 that uncovered a remarkably potent and selective class of aza-beta-lactam (ABL) PME-1 inhibitors.	lauric acid	205-208	protein phosphatase methylesterase 1	Homo sapiens	124-129
21639134-2	2011	We recently reported a fluorescence polarization-activity-based protein profiling (fluopol-ABPP) high-throughput screen for PME-1 that uncovered a remarkably potent and selective class of aza-beta-lactam (ABL) PME-1 inhibitors.	lauric acid	205-208	protein phosphatase methylesterase 1	Homo sapiens	210-215
21257711-4	2011	In this study, we provide evidence that the Abl-related nonreceptor tyrosine kinase Arg mediates epidermal growth factor (EGF)-induced cortactin phosphorylation, triggering actin polymerization in invadopodia, ECM degradation, and matrix proteolysis-dependent tumor cell invasion.	lauric acid	44-47	cortactin	Homo sapiens	135-144
21417343-0	2011	Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.	lauric acid	22-25	ABL proto-oncogene 2, non-receptor tyrosine kinase	Homo sapiens	40-44
21417343-1	2011	ABL2 (also known as ARG (ABL related gene)) is closely related to the well-studied Abelson kinase cABL.	lauric acid	0-3	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	98-102
21593191-5	2011	In addition, exposure of abl and C4-2B cells to CCI-779 also decreased UBE2C-dependent cell invasion.	lauric acid	25-28	ubiquitin conjugating enzyme E2 C	Homo sapiens	71-76
20060605-5	2011	Such growth-inhibitory effects of ABL were associated with G1 phase arrest, which were correlated with reduction of cyclins D1, A, and E expression and cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 proteins, increased the CDK inhibitory protein p21cip1 expression, and enhanced the binding of p21cip1 to CDKs.	lauric acid	34-37	cyclin dependent kinase 2	Rattus norvegicus	152-183
20060605-5	2011	Such growth-inhibitory effects of ABL were associated with G1 phase arrest, which were correlated with reduction of cyclins D1, A, and E expression and cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 proteins, increased the CDK inhibitory protein p21cip1 expression, and enhanced the binding of p21cip1 to CDKs.	lauric acid	34-37	cyclin-dependent kinase 4	Rattus norvegicus	185-189
20060605-5	2011	Such growth-inhibitory effects of ABL were associated with G1 phase arrest, which were correlated with reduction of cyclins D1, A, and E expression and cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 proteins, increased the CDK inhibitory protein p21cip1 expression, and enhanced the binding of p21cip1 to CDKs.	lauric acid	34-37	cyclin-dependent kinase 6	Rattus norvegicus	195-199
20060605-5	2011	Such growth-inhibitory effects of ABL were associated with G1 phase arrest, which were correlated with reduction of cyclins D1, A, and E expression and cyclin-dependent kinase (CDK) 2, CDK4, and CDK6 proteins, increased the CDK inhibitory protein p21cip1 expression, and enhanced the binding of p21cip1 to CDKs.	lauric acid	34-37	cyclin dependent kinase 2	Rattus norvegicus	306-310
20060605-6	2011	In addition, ABL also induced apoptosis in proliferative VSMCs, as evidenced by the induction of a higher ratio of Bax/Bcl-2, activation of caspase-9, caspase-3, and the cleavage of endogenous substrate Poly (ADP-ribose) polymerase.	lauric acid	13-16	BCL2 associated X, apoptosis regulator	Rattus norvegicus	115-118
20060605-6	2011	In addition, ABL also induced apoptosis in proliferative VSMCs, as evidenced by the induction of a higher ratio of Bax/Bcl-2, activation of caspase-9, caspase-3, and the cleavage of endogenous substrate Poly (ADP-ribose) polymerase.	lauric acid	13-16	BCL2, apoptosis regulator	Rattus norvegicus	119-124
20060605-6	2011	In addition, ABL also induced apoptosis in proliferative VSMCs, as evidenced by the induction of a higher ratio of Bax/Bcl-2, activation of caspase-9, caspase-3, and the cleavage of endogenous substrate Poly (ADP-ribose) polymerase.	lauric acid	13-16	caspase 9	Rattus norvegicus	140-149
20060605-6	2011	In addition, ABL also induced apoptosis in proliferative VSMCs, as evidenced by the induction of a higher ratio of Bax/Bcl-2, activation of caspase-9, caspase-3, and the cleavage of endogenous substrate Poly (ADP-ribose) polymerase.	lauric acid	13-16	caspase 3	Rattus norvegicus	151-160
20060605-8	2011	Furthermore, the effects of ABL on VSMCs were associated with the downregulation of extracellular signal-regulated kinase (ERK) 1/2 signaling pathways.	lauric acid	28-31	mitogen activated protein kinase 3	Rattus norvegicus	84-131
20060605-9	2011	In vivo, ABL (26 mg/kg/day) significantly suppressed injury-induced ERK1/2 phosphorylation, and increased VSMC apoptosis 14 days after balloon injury.	lauric acid	9-12	mitogen activated protein kinase 3	Rattus norvegicus	68-74
21300982-0	2011	c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5" region of Cdk6.	lauric acid	19-22	jun proto-oncogene	Mus musculus	0-5
21300982-0	2011	c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5" region of Cdk6.	lauric acid	19-22	cyclin-dependent kinase 6	Mus musculus	95-99
21300982-1	2011	The transcription factor c-JUN and its upstream kinase JNK1 have been implicated in BCR-ABL-induced leukemogenesis.	lauric acid	88-91	jun proto-oncogene	Mus musculus	25-30
21300982-1	2011	The transcription factor c-JUN and its upstream kinase JNK1 have been implicated in BCR-ABL-induced leukemogenesis.	lauric acid	88-91	mitogen-activated protein kinase 8	Mus musculus	55-59
21300982-5	2011	In c-Jun(Delta/Delta) cells, CDK6 expression becomes down-regulated upon BCR-ABL-induced transformation, which correlates with CpG island methylation within the 5" region of Cdk6.	lauric acid	77-80	jun proto-oncogene	Mus musculus	3-8
21300982-5	2011	In c-Jun(Delta/Delta) cells, CDK6 expression becomes down-regulated upon BCR-ABL-induced transformation, which correlates with CpG island methylation within the 5" region of Cdk6.	lauric acid	77-80	cyclin-dependent kinase 6	Mus musculus	29-33
21300982-5	2011	In c-Jun(Delta/Delta) cells, CDK6 expression becomes down-regulated upon BCR-ABL-induced transformation, which correlates with CpG island methylation within the 5" region of Cdk6.	lauric acid	77-80	cyclin-dependent kinase 6	Mus musculus	174-178
21300982-6	2011	We verified the impact of Cdk6 deficiency using Cdk6(-/-) mice that developed BCR-ABL-induced B-lymphoid leukemia with significantly increased latency and an attenuated disease phenotype.	lauric acid	82-85	cyclin-dependent kinase 6	Mus musculus	26-30
19554484-1	2010	Abelson interactor protein-1 (ABI1) is a promising candidate tumor suppressor, and plays critical roles both in the pathogenesis of BCR-Abl-induced leukemia and in the spread of several solid tumors.	lauric acid	136-139	abl interactor 1	Homo sapiens	0-28
20807813-0	2010	A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.	lauric acid	36-39	v-crk avian sarcoma virus CT10 oncogene homolog-like	Mus musculus	20-24
20886612-1	2010	ArgBP2 (Arg/Abl-Binding Protein) is expressed at high levels in the heart and is localized in the Z-bands of mature myofibrils.	lauric acid	12-15	sorbin and SH3 domain containing 2	Homo sapiens	0-6
19554484-1	2010	Abelson interactor protein-1 (ABI1) is a promising candidate tumor suppressor, and plays critical roles both in the pathogenesis of BCR-Abl-induced leukemia and in the spread of several solid tumors.	lauric acid	136-139	abl interactor 1	Homo sapiens	30-34
20632328-4	2010	In particular, we observed that the conversion of the fluorogenic peroxidase substrate Amplex Red by CYP119A1 and BMP was increased by a factor of 38 or 11, respectively, when isopropanol and lauric acid were present in the reaction mixture.	lauric acid	192-203	bone morphogenetic protein 1	Homo sapiens	114-117
20806084-6	2010	The saturated fatty acids (SFAs), such as palmitic acid (C16:0), myristic acid (C14:0), and lauric acid (C12:0), increase total plasma cholesterol, especially LDL, and constitute 11.3 g/L of bovine milk, which is 44.8% of total fatty acid in milk fat.	lauric acid	92-103	Weaning weight-maternal milk	Bos taurus	198-202
20806084-6	2010	The saturated fatty acids (SFAs), such as palmitic acid (C16:0), myristic acid (C14:0), and lauric acid (C12:0), increase total plasma cholesterol, especially LDL, and constitute 11.3 g/L of bovine milk, which is 44.8% of total fatty acid in milk fat.	lauric acid	92-103	Weaning weight-maternal milk	Bos taurus	242-246
19402756-8	2009	We tested whether ABL-1, the C. elegans ortholog of Abl, inhibits the CED-2 CrkII-dependent engulfment of apoptotic cells.	lauric acid	52-55	Tyrosine-protein kinase;Tyrosine-protein kinase abl-1;uncharacterized protein	Caenorhabditis elegans	18-23
20093159-2	2010	For this purpose, we modified the GLP-1 analog of exendin-4 using two fatty acids (FA) either lauric acid (LUA, C12) or palmitic acid (PAA, C16) at its two lysine residues, to produce; Lys(12)-FA-Exendin-4 (FA-M2), Lys(27)-FA-Exendin-4 (FA-M1), or Lys(12,27)-diBA-Exendin-4 (FA-Di).	lauric acid	94-105	glucagon	Mus musculus	34-39
20032992-3	2010	Incubation of lauric acid, palmitic acid, or oleic acid (OA) with human sebocytes dramatically enhanced their expression of human beta-defensin (hBD)-2, one of the predominant AMPs found in the skin, whereas remarkable increases in hBD-1, hBD-3, and human cathelicidin LL-37 were not observed.	lauric acid	14-25	defensin beta 4A	Homo sapiens	130-151
20032992-3	2010	Incubation of lauric acid, palmitic acid, or oleic acid (OA) with human sebocytes dramatically enhanced their expression of human beta-defensin (hBD)-2, one of the predominant AMPs found in the skin, whereas remarkable increases in hBD-1, hBD-3, and human cathelicidin LL-37 were not observed.	lauric acid	14-25	defensin beta 1	Homo sapiens	232-237
20032992-3	2010	Incubation of lauric acid, palmitic acid, or oleic acid (OA) with human sebocytes dramatically enhanced their expression of human beta-defensin (hBD)-2, one of the predominant AMPs found in the skin, whereas remarkable increases in hBD-1, hBD-3, and human cathelicidin LL-37 were not observed.	lauric acid	14-25	defensin beta 103B	Homo sapiens	239-244
19648648-4	2009	Here, we report for the first time that the saturated fatty acid lauric acid induced dimerization and recruitment of TLR4 into lipid rafts, however, dimerization was not observed in non-lipid raft fractions.	lauric acid	65-76	toll like receptor 4	Homo sapiens	117-121
19648648-5	2009	Similarly, LPS and lauric acid enhanced the association of TLR4 with MD-2 and downstream adaptor molecules, TRIF and MyD88, into lipid rafts leading to the activation of downstream signaling pathways and target gene expression.	lauric acid	19-30	toll like receptor 4	Homo sapiens	59-63
19648648-5	2009	Similarly, LPS and lauric acid enhanced the association of TLR4 with MD-2 and downstream adaptor molecules, TRIF and MyD88, into lipid rafts leading to the activation of downstream signaling pathways and target gene expression.	lauric acid	19-30	TIR domain containing adaptor molecule 1	Homo sapiens	108-112
19648648-5	2009	Similarly, LPS and lauric acid enhanced the association of TLR4 with MD-2 and downstream adaptor molecules, TRIF and MyD88, into lipid rafts leading to the activation of downstream signaling pathways and target gene expression.	lauric acid	19-30	MYD88 innate immune signal transduction adaptor	Homo sapiens	117-122
19648648-6	2009	However, docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, inhibited LPS- or lauric acid-induced dimerization and recruitment of TLR4 into lipid raft fractions.	lauric acid	90-101	toll like receptor 4	Homo sapiens	142-146
19648648-7	2009	Together, these results demonstrate that lauric acid and DHA reciprocally modulate TLR4 activation by regulation of the dimerization and recruitment of TLR4 into lipid rafts.	lauric acid	41-52	toll like receptor 4	Homo sapiens	83-87
19648648-7	2009	Together, these results demonstrate that lauric acid and DHA reciprocally modulate TLR4 activation by regulation of the dimerization and recruitment of TLR4 into lipid rafts.	lauric acid	41-52	toll like receptor 4	Homo sapiens	152-156
19694731-1	2009	BACKGROUND AND PURPOSE: Our previous study showed that urocortin (Ucn1) exacerbates the hypercoagulable state and vasculitis in a rat model of sodium laurate-induced thromboangiitis obliterans.	lauric acid	143-157	urocortin	Rattus norvegicus	55-64
19572944-2	2009	Here we have examined the effects of urocortin on sodium laurate-induced peripheral arterial vasculitis in rats, modelling the mechanisms of thromboangiitis obliterans (TAO).	lauric acid	50-64	urocortin	Rattus norvegicus	37-46
19572944-9	2009	Exogenous urocortin, given for 12 days after sodium laurate, exacerbated the hypercoagulable state and augmented expression of CRF(1alpha)-receptors, COX-2 and ICAM-1.	lauric acid	45-59	urocortin	Rattus norvegicus	10-19
19573409-11	2009	CD66c/CD10/CD34/CD19 expression was significantly higher in BCR/ABL positive group (P = 0.037) and relapsed patients group (P = 0.047).	lauric acid	64-67	CEA cell adhesion molecule 6	Homo sapiens	0-5
19573409-11	2009	CD66c/CD10/CD34/CD19 expression was significantly higher in BCR/ABL positive group (P = 0.037) and relapsed patients group (P = 0.047).	lauric acid	64-67	membrane metalloendopeptidase	Homo sapiens	6-10
19573409-11	2009	CD66c/CD10/CD34/CD19 expression was significantly higher in BCR/ABL positive group (P = 0.037) and relapsed patients group (P = 0.047).	lauric acid	64-67	CD34 molecule	Homo sapiens	11-15
20649041-1	2010	A hydrophobic low-density lipoprotein cholesterol (LDL-C) adsorbent was synthesized with lauric acid and chitosan.	lauric acid	89-100	component of oligomeric golgi complex 2	Homo sapiens	51-56
20212103-7	2010	The over-expression phenotype of dao is suppressed in a seizure mutant background, suggesting that Dao acts by an effect on Erg channels.	lauric acid	99-102	down and out	Drosophila melanogaster	33-36
20212103-7	2010	The over-expression phenotype of dao is suppressed in a seizure mutant background, suggesting that Dao acts by an effect on Erg channels.	lauric acid	99-102	seizure	Drosophila melanogaster	124-127
20212103-8	2010	In support of this hypothesis, functional expression of Erg channels in a heterologous system is dependent on the presence of Dao.	lauric acid	126-129	seizure	Drosophila melanogaster	56-59
20212103-9	2010	These results indicate that Dao has an important role in establishing the proper level of neuronal membrane excitability by regulating functional expression of Erg channels.	lauric acid	28-31	seizure	Drosophila melanogaster	160-163
19700560-7	2009	Recently, an anther-specific cytochrome P450, denoted CYP703A2, that catalyzes in-chain hydroxylation of lauric acid was also shown to be involved in sporopollenin synthesis.	lauric acid	105-116	cytochrome P450, family 703, subfamily A, polypeptide 2	Arabidopsis thaliana	54-62
19542491-0	2009	Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice.	lauric acid	0-3	breast cancer anti-estrogen resistance 1	Mus musculus	41-65
19542491-0	2009	Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice.	lauric acid	0-3	vinculin	Mus musculus	67-75
19542491-0	2009	Abl knockout differentially affects p130 Crk-associated substrate, vinculin, and paxillin in blood vessels of mice.	lauric acid	0-3	paxillin	Mus musculus	81-89
19542491-7	2009	The expression of vinculin and paxillin at protein and messenger levels was lower in arterial vessels from Abl knockout mice.	lauric acid	107-110	vinculin	Mus musculus	18-26
19542491-7	2009	The expression of vinculin and paxillin at protein and messenger levels was lower in arterial vessels from Abl knockout mice.	lauric acid	107-110	paxillin	Mus musculus	31-39
19542491-9	2009	These results indicate that Abl differentially regulates Crk-associated substrate, vinculin, and paxillin in arterial vessels.	lauric acid	28-31	breast cancer anti-estrogen resistance 1	Mus musculus	57-81
19542491-9	2009	These results indicate that Abl differentially regulates Crk-associated substrate, vinculin, and paxillin in arterial vessels.	lauric acid	28-31	vinculin	Mus musculus	83-91
19542491-9	2009	These results indicate that Abl differentially regulates Crk-associated substrate, vinculin, and paxillin in arterial vessels.	lauric acid	28-31	paxillin	Mus musculus	97-105
19366684-2	2009	Expression of CYP4A11 in mice yields liver and kidney P450 4A11 levels similar to those found in the corresponding human tissues and leads to an increased microsomal capacity for omega-hydroxylation of lauric acid.	lauric acid	202-213	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	14-21
21057560-6	2009	Moreover within the chronic phase patients the RHAMM positive patients had a significantly higher level of bcr-abl/abl ratio.	lauric acid	111-114	hyaluronan mediated motility receptor	Homo sapiens	47-52
19573409-11	2009	CD66c/CD10/CD34/CD19 expression was significantly higher in BCR/ABL positive group (P = 0.037) and relapsed patients group (P = 0.047).	lauric acid	64-67	CD19 molecule	Homo sapiens	16-20
19402756-8	2009	We tested whether ABL-1, the C. elegans ortholog of Abl, inhibits the CED-2 CrkII-dependent engulfment of apoptotic cells.	lauric acid	52-55	Cell death abnormality protein 2;SH3 domain-containing protein	Caenorhabditis elegans	70-75
19634451-3	2009	The binding interaction between HSA and acetic acid (C2), octanoic acid (C8) and dodecanoic acid (C12) has been investigated by the combination of site-specific fluorescent probe, tryptophan intrinsic fluorescence and tyrosine electrochemistry.	lauric acid	81-96	albumin	Homo sapiens	32-35
19236814-0	2009	Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.	lauric acid	80-83	runt related transcription factor 1	Mus musculus	32-67
19090726-0	2009	Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid.	lauric acid	53-64	cytochrome P450 family 4 subfamily Z member 1	Homo sapiens	6-12
19120447-3	2009	Lauric acid (C(12:0)) was converted into a mixture of hydroxylauric acids when incubated with microsomes from yeast expressing CYP77A4.	lauric acid	0-11	cytochrome P450, family 77, subfamily A, polypeptide 4	Arabidopsis thaliana	127-134
19053923-8	2008	RESULTS: In the univariate analysis, allele 2 of IL-1B+3954 and IL-1B-511 was associated with ABL (P = 0.040 and P = 0.039, respectively), whereas no association was found with allele 2 of IL-1A+4845 or IL-1RN variable number tandem repeat (VNTR) (P = 0.445 and P = 0.375, respectively).	lauric acid	94-97	interleukin 1 beta	Homo sapiens	49-54
18621416-14	2008	After FLAI-GO, the mean value of WT1 dropped from 4200+/-2777 copies/10(4)ABL to 192+/-399 copies/10(4)ABL.	lauric acid	74-77	WT1 transcription factor	Homo sapiens	33-36
19053923-8	2008	RESULTS: In the univariate analysis, allele 2 of IL-1B+3954 and IL-1B-511 was associated with ABL (P = 0.040 and P = 0.039, respectively), whereas no association was found with allele 2 of IL-1A+4845 or IL-1RN variable number tandem repeat (VNTR) (P = 0.445 and P = 0.375, respectively).	lauric acid	94-97	interleukin 1 beta	Homo sapiens	64-69
19053923-9	2008	A lower ABL was associated with the occurrence of allele 2 of IL-1B-511.	lauric acid	8-11	interleukin 1 beta	Homo sapiens	62-67
19053923-10	2008	The multiple logistic regression analysis also showed a significant association of allele 1 of IL-1B-511 with high ABL (P = 0.049) and of allele 2 of IL-1A+4845 with high ABL among individuals with CHD (P = 0.050).	lauric acid	115-118	interleukin 1 beta	Homo sapiens	95-100
18559973-0	2008	Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.	lauric acid	42-45	S-phase kinase-associated protein 2	Mus musculus	11-15
18625543-6	2008	CD spectra show that complexes of polyampholyte and fluorinated dodecanoic acid induce alpha-helix structure in Abeta, but their hydrogenated analogous lead to beta-sheet formation and aggregation.	lauric acid	64-79	amyloid beta precursor protein	Homo sapiens	112-117
18453543-6	2008	Abi1 contributes to Bcr-Abl-induced leukemogenesis in part through Src family kinases, as the knock down of Abi1 expression attenuates Bcr-Abl-stimulated activation of Lyn.	lauric acid	24-27	abl interactor 1	Mus musculus	0-4
18453543-6	2008	Abi1 contributes to Bcr-Abl-induced leukemogenesis in part through Src family kinases, as the knock down of Abi1 expression attenuates Bcr-Abl-stimulated activation of Lyn.	lauric acid	24-27	abl interactor 1	Mus musculus	108-112
18453543-0	2008	Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.	lauric acid	53-56	abl interactor 1	Mus musculus	0-4
18453543-6	2008	Abi1 contributes to Bcr-Abl-induced leukemogenesis in part through Src family kinases, as the knock down of Abi1 expression attenuates Bcr-Abl-stimulated activation of Lyn.	lauric acid	24-27	LYN proto-oncogene, Src family tyrosine kinase	Mus musculus	168-171
18453543-3	2008	We show here that Abi1 gene silencing by short hairpin RNA attenuated the Bcr-Abl-induced abnormal actin remodeling, membrane-type 1 metalloproteinase clustering and inhibited cell adhesion and migration on fibronectin-coated surfaces.	lauric acid	78-81	abl interactor 1	Mus musculus	18-22
18642865-4	2008	Fluorogenic caspase-3 substrates 11 and 13 derived from umbelliferone and DAO, respectively, were prepared.	lauric acid	74-77	caspase 3	Homo sapiens	12-21
18453543-3	2008	We show here that Abi1 gene silencing by short hairpin RNA attenuated the Bcr-Abl-induced abnormal actin remodeling, membrane-type 1 metalloproteinase clustering and inhibited cell adhesion and migration on fibronectin-coated surfaces.	lauric acid	78-81	fibronectin 1	Mus musculus	207-218
18068630-4	2007	Moreover, beta-catenin deletion causes a profound reduction in the ability of mice to develop BCR-ABL-induced chronic myelogenous leukemia (CML), while allowing progression of acute lymphocytic leukemia (ALL).	lauric acid	98-101	catenin (cadherin associated protein), beta 1	Mus musculus	10-22
18548107-3	2008	BTK has been implicated in Bcr-Abl-mediated B-cell transformation and resistance to imatinib, implying that inhibiting BTK may be therapeutically beneficial.	lauric acid	31-34	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	0-3
18548107-3	2008	BTK has been implicated in Bcr-Abl-mediated B-cell transformation and resistance to imatinib, implying that inhibiting BTK may be therapeutically beneficial.	lauric acid	31-34	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	119-122
18355012-1	2008	The adsorption, desorption, and equilibrium monomer exchange processes of sodium dodecanoate at the fluorite(CaF 2)-water interface have been studied.	lauric acid	74-92	CCR4-NOT transcription complex subunit 8	Homo sapiens	109-114
18407910-9	2008	A so-called structured lipid composed of the medium-chain fatty acid dodecanoic acid on the 2 position and long-chain fatty acids on the 1 and 3 positions appeared to be endogenously synthesized in response to the LCT/2mono diet.	lauric acid	69-84	lactase	Rattus norvegicus	214-217
18187312-0	2008	Lauric acid dependent enhancement in hepatic SCPx protein requires an insulin deficient environment.	lauric acid	0-11	sterol carrier protein 2	Rattus norvegicus	45-49
18187312-2	2008	Treating with the fatty acid, lauric acid, induced SCPx mRNA levels in rat liver and in rat hepatoma H4IIE cells but enhanced protein levels of SCPx and the thiolase produced as a post-translational modification of SCPx were only seen in H4IIE cells.	lauric acid	30-41	sterol carrier protein 2	Rattus norvegicus	51-55
18187312-2	2008	Treating with the fatty acid, lauric acid, induced SCPx mRNA levels in rat liver and in rat hepatoma H4IIE cells but enhanced protein levels of SCPx and the thiolase produced as a post-translational modification of SCPx were only seen in H4IIE cells.	lauric acid	30-41	sterol carrier protein 2	Rattus norvegicus	144-148
18187312-2	2008	Treating with the fatty acid, lauric acid, induced SCPx mRNA levels in rat liver and in rat hepatoma H4IIE cells but enhanced protein levels of SCPx and the thiolase produced as a post-translational modification of SCPx were only seen in H4IIE cells.	lauric acid	30-41	sterol carrier protein 2	Rattus norvegicus	144-148
18187312-3	2008	Further investigation revealed that the presence of insulin can mask lauric acid effects on the SCPx gene especially at the protein level.	lauric acid	69-80	sterol carrier protein 2	Rattus norvegicus	96-100
19238188-7	2008	Introduction of lauric acid residue (Ki = 1,76 muM) maximally increased the inhibition effect.	lauric acid	16-27	latexin	Homo sapiens	47-50
17928047-1	2008	The complexations between catalase and the sodium perfluorooctanoate/sodium octanoate and sodium perfluorooctanoate/sodium dodecanoate systems have been studied by a combination of electrophoresis and spectroscopy measurements.	lauric acid	116-134	catalase	Homo sapiens	26-34
17587335-7	2007	Yeast two-hybrid and coimmunoprecipitation analyses demonstrated that AnkA could bind to Abl-interactor 1 (Abi-1), an adaptor protein that interacts with Abl-1 tyrosine kinase, thus mediating AnkA phosphorylation.	lauric acid	89-92	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	154-159
17572088-2	2007	The optimized combi-molecule 13a was shown to induce approximately twofold stronger abl TK inhibitory activity than Gleevec and high levels of DNA damage in chronic myelogenous leukemic cells.	lauric acid	84-87	TXK tyrosine kinase	Homo sapiens	88-90
17400174-4	2007	The purified protein, reconstituted with rat NADPH-cytochrome P450 reductase, omega-hydroxylated dodecanoic acid to give 12-hydroxydodecanoic acid, but to a lesser extent also catalyzed (omega-1)-hydroxylation to give 11-hydroxydodecanoic acid.	lauric acid	97-112	cytochrome p450 oxidoreductase	Rattus norvegicus	45-76
17543336-4	2007	Abl-binding proteins bound to a proline-rich region of PAK-2 located in the regulatory N terminus.	lauric acid	0-3	p21 (RAC1) activated kinase 2	Homo sapiens	55-60
17543336-6	2007	Interestingly, we show that PAK-2 also interacted with c-Abl but via a different domain than with the Abl-binding proteins.	lauric acid	57-60	p21 (RAC1) activated kinase 2	Homo sapiens	28-33
17496121-8	2007	Heterologous expression of CYP703A2 in yeast cells demonstrated that CYP703 catalyzes the conversion of medium-chain saturated fatty acids to the corresponding monohydroxylated fatty acids, with a preferential hydroxylation of lauric acid at the C-7 position.	lauric acid	227-238	cytochrome P450, family 703, subfamily A, polypeptide 2	Arabidopsis thaliana	27-35
17237826-0	2007	c-Cbl-facilitated cytoskeletal effects in v-Abl-transformed fibroblasts are regulated by membrane association of c-Cbl.	lauric acid	44-47	Cbl proto-oncogene	Homo sapiens	0-5
17237826-0	2007	c-Cbl-facilitated cytoskeletal effects in v-Abl-transformed fibroblasts are regulated by membrane association of c-Cbl.	lauric acid	44-47	Cbl proto-oncogene	Homo sapiens	113-118
17331985-0	2007	Effects of lauric acid on upper gut motility, plasma cholecystokinin and peptide YY, and energy intake are load, but not concentration, dependent in humans.	lauric acid	11-22	peptide YY	Homo sapiens	73-83
17331985-2	2007	We postulated that, in humans, the modulation of antropyloroduodenal pressure waves, plasma cholecystokinin (CCK) and peptide YY (PYY) concentrations and energy intake by intraduodenal lauric acid, a fatty acid with 12 carbon atoms ("C12") would be load, but not concentration, dependent.	lauric acid	185-196	cholecystokinin	Homo sapiens	109-112
17331985-2	2007	We postulated that, in humans, the modulation of antropyloroduodenal pressure waves, plasma cholecystokinin (CCK) and peptide YY (PYY) concentrations and energy intake by intraduodenal lauric acid, a fatty acid with 12 carbon atoms ("C12") would be load, but not concentration, dependent.	lauric acid	185-196	peptide YY	Homo sapiens	118-128
17331985-2	2007	We postulated that, in humans, the modulation of antropyloroduodenal pressure waves, plasma cholecystokinin (CCK) and peptide YY (PYY) concentrations and energy intake by intraduodenal lauric acid, a fatty acid with 12 carbon atoms ("C12") would be load, but not concentration, dependent.	lauric acid	185-196	peptide YY	Homo sapiens	130-133
17303577-5	2007	Lauric acid (C12:0) dose dependently activated NF-kappaB and induced IL-8 expression in HCT116 cells, which express both Nod1 and Nod2, but not detectable amounts of TLR2 and TLR4.	lauric acid	0-11	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
17303577-5	2007	Lauric acid (C12:0) dose dependently activated NF-kappaB and induced IL-8 expression in HCT116 cells, which express both Nod1 and Nod2, but not detectable amounts of TLR2 and TLR4.	lauric acid	0-11	nucleotide binding oligomerization domain containing 1	Homo sapiens	121-125
17303577-5	2007	Lauric acid (C12:0) dose dependently activated NF-kappaB and induced IL-8 expression in HCT116 cells, which express both Nod1 and Nod2, but not detectable amounts of TLR2 and TLR4.	lauric acid	0-11	nucleotide binding oligomerization domain containing 2	Homo sapiens	130-134
17303577-6	2007	These effects of lauric acid were inhibited by dominant negative forms of Nod1 or Nod2, but not by dominant negative forms of TLR2, TLR4, and TLR5.	lauric acid	17-28	nucleotide binding oligomerization domain containing 1	Homo sapiens	74-78
17303577-6	2007	These effects of lauric acid were inhibited by dominant negative forms of Nod1 or Nod2, but not by dominant negative forms of TLR2, TLR4, and TLR5.	lauric acid	17-28	nucleotide binding oligomerization domain containing 2	Homo sapiens	82-86
17303577-7	2007	The effects of lauric acid were also attenuated by small RNA interference targeting Nod1 or Nod2.	lauric acid	15-26	nucleotide binding oligomerization domain containing 1	Homo sapiens	84-88
17303577-7	2007	The effects of lauric acid were also attenuated by small RNA interference targeting Nod1 or Nod2.	lauric acid	15-26	nucleotide binding oligomerization domain containing 2	Homo sapiens	92-96
17303577-8	2007	In contrast, polyunsaturated fatty acids, especially n-3 polyunsaturated fatty acids, inhibited the activation of NF-kappaB and IL-8 expression induced by lauric acid or known Nods ligands in HCT116.	lauric acid	155-166	C-X-C motif chemokine ligand 8	Homo sapiens	128-132
17303577-9	2007	Furthermore, lauric acid induced, but docosahexaenoic acid inhibited lauric acid- or Nod2 ligand MDP-induced, Nod2 oligomerization in HEK293T cells transfected with Nod2.	lauric acid	69-80	nucleotide binding oligomerization domain containing 2	Homo sapiens	110-114
17303577-9	2007	Furthermore, lauric acid induced, but docosahexaenoic acid inhibited lauric acid- or Nod2 ligand MDP-induced, Nod2 oligomerization in HEK293T cells transfected with Nod2.	lauric acid	69-80	nucleotide binding oligomerization domain containing 2	Homo sapiens	110-114
16771408-1	2006	The complexations between human serum albumin (HSA) and the sodium perfluorooctanoate/sodium octanoate and sodium perfluorooctanoate/sodium dodecanoate systems have been studied by a combination of electrical conductivity, ion-selective electrode, electrophoresis, and spectroscopy measurements.	lauric acid	133-151	albumin	Homo sapiens	32-51
17252012-2	2007	Expression data reflected several BCR-ABL-induced effects in primary CML progenitors, such as transcriptional activation of the classical mitogen-activated protein kinase pathway and the phosphoinositide-3 kinase/AKT pathway as well as downregulation of the proapoptotic gene IRF8.	lauric acid	38-41	AKT serine/threonine kinase 1	Homo sapiens	213-216
17252012-2	2007	Expression data reflected several BCR-ABL-induced effects in primary CML progenitors, such as transcriptional activation of the classical mitogen-activated protein kinase pathway and the phosphoinositide-3 kinase/AKT pathway as well as downregulation of the proapoptotic gene IRF8.	lauric acid	38-41	interferon regulatory factor 8	Homo sapiens	276-280
16707466-9	2006	In concordance with this, the Abl ATP-binding pocket domain of Bcr/Abl in the resistant cells did not contain point mutations which would make the protein Imatinib resistant.	lauric acid	30-33	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	63-70
15961531-1	2005	We recently reported that intraduodenal infusion of lauric acid (C12) (0.375 kcal/min, 106 mM) stimulates isolated pyloric pressure waves (IPPWs), inhibits antral and duodenal pressure waves (PWs), stimulates release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), and suppresses energy intake and that these effects are much greater than those seen in response to isocaloric decanoic acid (C10) infusion.	lauric acid	52-63	cholecystokinin	Homo sapiens	220-235
16441434-0	2006	Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus.	lauric acid	0-3	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	22-25
16719385-1	2006	Lauric acid serves as an endogenous substrate for the cytochrome P450 enzyme CYP4A11.	lauric acid	0-11	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	77-84
16719385-2	2006	A reverse-phase, high-performance liquid chromatography method is described for the quantification of 12-hydroxylauric acid formed enzymatically by incubation of 14C-labeled lauric acid with cDNA-expressed CYP4A11 or human liver microsomes.	lauric acid	112-123	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	206-213
15961531-1	2005	We recently reported that intraduodenal infusion of lauric acid (C12) (0.375 kcal/min, 106 mM) stimulates isolated pyloric pressure waves (IPPWs), inhibits antral and duodenal pressure waves (PWs), stimulates release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), and suppresses energy intake and that these effects are much greater than those seen in response to isocaloric decanoic acid (C10) infusion.	lauric acid	52-63	cholecystokinin	Homo sapiens	237-240
15961531-1	2005	We recently reported that intraduodenal infusion of lauric acid (C12) (0.375 kcal/min, 106 mM) stimulates isolated pyloric pressure waves (IPPWs), inhibits antral and duodenal pressure waves (PWs), stimulates release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), and suppresses energy intake and that these effects are much greater than those seen in response to isocaloric decanoic acid (C10) infusion.	lauric acid	52-63	glucagon	Homo sapiens	246-269
15961531-1	2005	We recently reported that intraduodenal infusion of lauric acid (C12) (0.375 kcal/min, 106 mM) stimulates isolated pyloric pressure waves (IPPWs), inhibits antral and duodenal pressure waves (PWs), stimulates release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), and suppresses energy intake and that these effects are much greater than those seen in response to isocaloric decanoic acid (C10) infusion.	lauric acid	52-63	glucagon	Homo sapiens	271-276
15961531-1	2005	We recently reported that intraduodenal infusion of lauric acid (C12) (0.375 kcal/min, 106 mM) stimulates isolated pyloric pressure waves (IPPWs), inhibits antral and duodenal pressure waves (PWs), stimulates release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), and suppresses energy intake and that these effects are much greater than those seen in response to isocaloric decanoic acid (C10) infusion.	lauric acid	52-63	chromosome 12 open reading frame 57	Homo sapiens	405-408
15927833-11	2005	The activity of HDC was significantly higher in cancerous tissues than in adjacent healthy tissues (54.7+/-17.1 vs. 34.5+/-24.3 pmol/min per mg; P<0.001), but there was no difference in the activity of DAO (14.0+/-6.4 vs. 14.4+/-10.9 pmol/min per mg).	lauric acid	205-208	histidine decarboxylase	Homo sapiens	16-19
15980100-9	2005	Although high concentrations of the substrate lauric acid increased BiFC for both P450 2E1 and P450 2C2 with P450 reductase, the concentration dependence did not correlate with reported K(m) values.	lauric acid	46-57	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	82-86
15980100-9	2005	Although high concentrations of the substrate lauric acid increased BiFC for both P450 2E1 and P450 2C2 with P450 reductase, the concentration dependence did not correlate with reported K(m) values.	lauric acid	46-57	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	95-99
15980100-9	2005	Although high concentrations of the substrate lauric acid increased BiFC for both P450 2E1 and P450 2C2 with P450 reductase, the concentration dependence did not correlate with reported K(m) values.	lauric acid	46-57	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	95-99
16181534-5	2005	(3) Compared with control group and sham operation groups, there was a decrease in tPA activity of model rats at the initial 12 h after injection of sodium laurate (P < 0.05), PAI activity decreased markedly in the model group at 24 h after injection of sodium laurate.	lauric acid	149-163	serpin family E member 1	Rattus norvegicus	179-182
16025998-5	2005	Protein e3B1/Abi-1, which belongs to the family of Abl-interactors, was isolated recently as a possible tumour suppressor.	lauric acid	51-54	abl interactor 1	Homo sapiens	8-12
16025998-5	2005	Protein e3B1/Abi-1, which belongs to the family of Abl-interactors, was isolated recently as a possible tumour suppressor.	lauric acid	51-54	abl interactor 1	Homo sapiens	13-18
15843537-4	2005	The results presented in this study demonstrate that the saturated fatty acid, lauric acid, up-regulates the expression of costimulatory molecules (CD40, CD80, and CD86), MHC class II, and cytokines (IL-12p70 and IL-6) in bone marrow-derived DCs.	lauric acid	79-90	CD80 molecule	Homo sapiens	154-158
15843537-4	2005	The results presented in this study demonstrate that the saturated fatty acid, lauric acid, up-regulates the expression of costimulatory molecules (CD40, CD80, and CD86), MHC class II, and cytokines (IL-12p70 and IL-6) in bone marrow-derived DCs.	lauric acid	79-90	CD40 molecule	Homo sapiens	148-152
15843537-4	2005	The results presented in this study demonstrate that the saturated fatty acid, lauric acid, up-regulates the expression of costimulatory molecules (CD40, CD80, and CD86), MHC class II, and cytokines (IL-12p70 and IL-6) in bone marrow-derived DCs.	lauric acid	79-90	CD86 molecule	Homo sapiens	164-168
15843537-4	2005	The results presented in this study demonstrate that the saturated fatty acid, lauric acid, up-regulates the expression of costimulatory molecules (CD40, CD80, and CD86), MHC class II, and cytokines (IL-12p70 and IL-6) in bone marrow-derived DCs.	lauric acid	79-90	interleukin 6	Homo sapiens	213-217
15843537-5	2005	The dominant negative mutant of TLR4 or its downstream signaling components inhibits lauric acid-induced expression of a CD86 promoter-reporter gene.	lauric acid	85-96	toll like receptor 4	Homo sapiens	32-36
15843537-5	2005	The dominant negative mutant of TLR4 or its downstream signaling components inhibits lauric acid-induced expression of a CD86 promoter-reporter gene.	lauric acid	85-96	CD86 molecule	Homo sapiens	121-125
14966134-4	2004	A saturated fatty acid, lauric acid, induced NFkappaB activation when TLR2 was co-transfected with TLR1 or TLR6 in 293T cells, but not when TLR1, 2, 3, 5, 6, or 9 was transfected individually.	lauric acid	24-35	toll like receptor 2	Homo sapiens	70-74
15895287-2	2005	Among isoforms of the CYP4A subfamily, CYP4A11 is a major lauric acid (medium-length fatty acids) omega hydroxylase and is involved in the balance of lipids in the human liver.	lauric acid	58-69	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	39-46
15555597-0	2004	Drosophila melanogaster CYP6A8, an insect P450 that catalyzes lauric acid (omega-1)-hydroxylation.	lauric acid	62-73	Cytochrome P450-6a8	Drosophila melanogaster	24-30
15555597-6	2004	Although several saturated or non-saturated fatty acids were not metabolized by CYP6A8, lauric acid (C12:0), a short-chain unsaturated fatty acid, was oxidized by CYP6A8 to produce 11-hydroxylauric acid with an apparent V(max) of 25 nmol/min/nmol P450.	lauric acid	88-99	Cytochrome P450-6a8	Drosophila melanogaster	163-169
15453498-0	2004	Effect of sodium laurate on ruminal fermentation and utilization of ruminal ammonia nitrogen for milk protein synthesis in dairy cows.	lauric acid	10-24	casein beta	Bos taurus	97-109
15138293-2	2004	We demonstrate that the Abl-related gene (Arg) nonreceptor tyrosine kinase is required for dynamic lamellipodial protrusions after adhesion to fibronectin.	lauric acid	24-27	fibronectin 1	Homo sapiens	143-154
15166004-2	2004	We postulated that intraduodenal administration of lauric acid (12 carbon atoms; C12) would suppress appetite, modulate antropyloroduodenal pressure waves (PWs), and stimulate the release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) more than an identical dose of decanoic acid (10 carbon atoms; C10).	lauric acid	51-62	cholecystokinin	Homo sapiens	191-206
15166004-2	2004	We postulated that intraduodenal administration of lauric acid (12 carbon atoms; C12) would suppress appetite, modulate antropyloroduodenal pressure waves (PWs), and stimulate the release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) more than an identical dose of decanoic acid (10 carbon atoms; C10).	lauric acid	51-62	cholecystokinin	Homo sapiens	208-211
15166004-2	2004	We postulated that intraduodenal administration of lauric acid (12 carbon atoms; C12) would suppress appetite, modulate antropyloroduodenal pressure waves (PWs), and stimulate the release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) more than an identical dose of decanoic acid (10 carbon atoms; C10).	lauric acid	51-62	glucagon	Homo sapiens	217-240
15166004-2	2004	We postulated that intraduodenal administration of lauric acid (12 carbon atoms; C12) would suppress appetite, modulate antropyloroduodenal pressure waves (PWs), and stimulate the release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) more than an identical dose of decanoic acid (10 carbon atoms; C10).	lauric acid	51-62	glucagon	Homo sapiens	242-247
15166004-2	2004	We postulated that intraduodenal administration of lauric acid (12 carbon atoms; C12) would suppress appetite, modulate antropyloroduodenal pressure waves (PWs), and stimulate the release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1) more than an identical dose of decanoic acid (10 carbon atoms; C10).	lauric acid	51-62	chromosome 12 open reading frame 57	Homo sapiens	312-315
15604745-8	2004	Therefore, we hypothesize that SAHH associates with DAO as part of a larger multienzyme complex that may function in planta as a nicotine metabolic channel.	lauric acid	52-55	adenosylhomocysteinase	Nicotiana tabacum	31-35
14764444-2	2004	Fatty acid release of CCK is chain-length sensitive; dodecanoic acid (C12) induces greater CCK release than decanoic acid (C10).	lauric acid	53-68	cholecystokinin	Homo sapiens	22-25
14764444-2	2004	Fatty acid release of CCK is chain-length sensitive; dodecanoic acid (C12) induces greater CCK release than decanoic acid (C10).	lauric acid	53-68	cholecystokinin	Homo sapiens	91-94
14966134-4	2004	A saturated fatty acid, lauric acid, induced NFkappaB activation when TLR2 was co-transfected with TLR1 or TLR6 in 293T cells, but not when TLR1, 2, 3, 5, 6, or 9 was transfected individually.	lauric acid	24-35	toll like receptor 1	Homo sapiens	99-103
14966134-4	2004	A saturated fatty acid, lauric acid, induced NFkappaB activation when TLR2 was co-transfected with TLR1 or TLR6 in 293T cells, but not when TLR1, 2, 3, 5, 6, or 9 was transfected individually.	lauric acid	24-35	toll like receptor 6	Homo sapiens	107-111
14966134-8	2004	Together, these results demonstrate that lauric acid activates TLR2 dimers as well as TLR4 for which respective bacterial agonists require acylated fatty acids, whereas DHA inhibits the activation of all TLRs tested.	lauric acid	41-52	toll like receptor 2	Homo sapiens	63-67
14699618-4	2004	Further FISH studies showed the translocation breakpoint on 9q34.11 maps proximal to ABL, between the BAC clone RP11-88G17 and the LMX1B gene.	lauric acid	85-88	pre-mRNA processing factor 31	Homo sapiens	112-116
14634044-4	2004	Substrate-binding assays indicated that leukotriene B(4) (LTB(4)) and arachidonic acid bound CYP4F1 and CYP4F4 in a type-I manner with a K(s) of 25 to 59 microM, and lauric acid bound CYP4F4 poorly.	lauric acid	166-177	cytochrome P450, family 4, subfamily f, polypeptide 1	Rattus norvegicus	93-99
14634044-4	2004	Substrate-binding assays indicated that leukotriene B(4) (LTB(4)) and arachidonic acid bound CYP4F1 and CYP4F4 in a type-I manner with a K(s) of 25 to 59 microM, and lauric acid bound CYP4F4 poorly.	lauric acid	166-177	cytochrome P450, family 4, subfamily f, polypeptide 4	Rattus norvegicus	104-110
14660610-6	2004	In addition to omega/omega-1 hydroxylation of arachidonic acid, CYP2U1 protein also catalyzed the hydroxylation of structurally related long chain fatty acid (docosahexaenoic acid) but not fatty acids such as lauric acid or linoleic acid.	lauric acid	209-220	cytochrome P450 family 2 subfamily U member 1	Homo sapiens	64-70
14757063-4	2004	Isothermal titration calorimetry experiments have revealed a thermodynamic signature for this interaction (very favourable enthalpic contributions opposed by an unfavourable binding entropy) inconsistent with the highly hydrophobic nature of the p41 ligand and the Abl-SH3 binding site.	lauric acid	265-268	mitogen-activated protein kinase 1	Homo sapiens	246-249
14555726-11	2003	In the presence of sulfate, STC-1 cells will only respond to dodecanoic acid aggregates whereas when sulfate is replaced with chloride the cells clearly respond to dodecanoic acid monomers which are completely in solution.	lauric acid	164-179	stanniocalcin 1	Mus musculus	28-33
14555726-10	2003	We finally resolved this issue with the observation that the sulfate ion greatly altered the response of STC-1 cells to monomeric dodecanoic acid.	lauric acid	130-145	stanniocalcin 1	Mus musculus	105-110
14555726-12	2003	In summary, we propose that dodecanoic acid can stimulate STC-1 cells via two separate pathways one involving fatty acid monomers in solution and one involving fatty acid aggregates.	lauric acid	28-43	stanniocalcin 1	Mus musculus	58-63
14555726-11	2003	In the presence of sulfate, STC-1 cells will only respond to dodecanoic acid aggregates whereas when sulfate is replaced with chloride the cells clearly respond to dodecanoic acid monomers which are completely in solution.	lauric acid	61-76	stanniocalcin 1	Mus musculus	28-33
12935973-0	2003	The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.	lauric acid	77-80	BCR activator of RhoGEF and GTPase	Homo sapiens	73-76
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	43-51
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	toll-like receptor 4	Mus musculus	110-114
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	myeloid differentiation primary response gene 88	Mus musculus	116-121
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	interleukin-1 receptor-associated kinase 1	Mus musculus	123-129
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	TNF receptor-associated factor 6	Mus musculus	131-136
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	141-153
12865424-4	2003	Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2.	lauric acid	22-33	toll like receptor 4	Homo sapiens	212-216
12865424-5	2003	Lauric acid induced the transient phosphorylation of AKT.	lauric acid	0-11	AKT serine/threonine kinase 1	Homo sapiens	53-56
12865424-6	2003	LY294002, dominant-negative (DN) phosphatidylinositol 3-kinase (PI3K), or AKT(DN) inhibited NFkappaB activation, p65 transactivation, and cyclooxygenase-2 (COX-2) expression induced by lauric acid or constitutively active (CA) TLR4.	lauric acid	185-196	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	33-62
12865424-9	2003	These results demonstrate that NFkappaB activation and COX-2 expression induced by lauric acid are at least partly mediated through the TLR4/PI3K/AKT signaling pathway.	lauric acid	83-94	nuclear factor kappa B subunit 1	Homo sapiens	31-39
12865424-9	2003	These results demonstrate that NFkappaB activation and COX-2 expression induced by lauric acid are at least partly mediated through the TLR4/PI3K/AKT signaling pathway.	lauric acid	83-94	prostaglandin-endoperoxide synthase 2	Homo sapiens	55-60
12865424-9	2003	These results demonstrate that NFkappaB activation and COX-2 expression induced by lauric acid are at least partly mediated through the TLR4/PI3K/AKT signaling pathway.	lauric acid	83-94	toll like receptor 4	Homo sapiens	136-140
12865424-9	2003	These results demonstrate that NFkappaB activation and COX-2 expression induced by lauric acid are at least partly mediated through the TLR4/PI3K/AKT signaling pathway.	lauric acid	83-94	AKT serine/threonine kinase 1	Homo sapiens	146-149
12865424-10	2003	In contrast, docosahexaenoic acid (DHA) inhibited the phosphorylation of AKT induced by lipopolysaccharide or lauric acid.	lauric acid	110-121	AKT serine/threonine kinase 1	Homo sapiens	73-76
14500898-3	2003	These results suggested that cytokine-independent IL-3 receptor activation could be a dominant signaling component in BCR-ABL-induced leukemogenesis.	lauric acid	122-125	interleukin 3	Mus musculus	50-54
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	127-133
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	135-141
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	143-149
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	151-157
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	159-165
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	167-173
12818727-5	2003	Ethoxyresorufin, coumarin, benzoxyresorufin, chlorzoxazone, testosterone and lauric acid were used as selective substrates for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2E1, CYP3A4 and CYP4A, respectively.	lauric acid	77-88	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	175-181
12595307-5	2003	Thus, in the mouse, the limited ability of imatinib mesylate to cross the blood-brain barrier allowed the CNS to become a sanctuary for Bcr/Abl-induced leukemia.	lauric acid	140-143	BCR activator of RhoGEF and GTPase	Mus musculus	136-139
12071844-4	2002	Expression of Ant1p as well as other enzymes whose genes are known to be regulated by a canonical ORE was found to be increased in cells grown on lauric acid, a medium-chain fatty acid.	lauric acid	146-157	Ant1p	Saccharomyces cerevisiae S288C	14-19
12626632-4	2003	Paired-pulse facilitation (PPF) was significantly reduced at the Schaffer collateral-CA1 (SC-CA1) excitatory synapses in hippocampal slices from abl-/- and arg-/- mice as compared with wild-type mice.	lauric acid	145-148	carbonic anhydrase 1	Mus musculus	85-88
12626632-4	2003	Paired-pulse facilitation (PPF) was significantly reduced at the Schaffer collateral-CA1 (SC-CA1) excitatory synapses in hippocampal slices from abl-/- and arg-/- mice as compared with wild-type mice.	lauric acid	145-148	carbonic anhydrase 1	Mus musculus	93-96
12479871-3	2003	The wild type UCP1 was associated with the FA-induced H+ uniport proportional to the added protein with a Km for lauric acid of 43 micro M and Vmax of 18 micro molmin(-1)(mg protein)(-1).	lauric acid	113-124	uncoupling protein 1	Homo sapiens	14-18
12716665-14	2003	The effects of carbohydrates and of lauric acid-rich fats on CAD risk remain uncertain.	lauric acid	36-47	chromosome 10 open reading frame 90	Homo sapiens	53-57
12624756-6	2003	Amino acid sequence of the hamster DAO was highly similar to those of mouse and rat DAOs: 89% and 88% of the amino acid residues were identical between the hamster and mouse DAOs and between the hamster and rat DAOs, respectively.	lauric acid	84-88	D-amino-acid oxidase	Cavia porcellus	35-38
12443881-3	2002	Amifostine at 14 mM decreased DNA-damaging effect of idarubicin in human lymphocytes and BaF3 cells, but increased the effect in TEL/ABL-transformed cells.	lauric acid	133-136	ets variant 6	Mus musculus	129-132
12360300-0	2002	Robo is Abl to block N-Cadherin function.	lauric acid	8-11	cadherin 2	Homo sapiens	21-31
11724808-3	2002	Curiously, the rate of methyl-beta-cyclodextrin-sensitive endocytosis of AMF-R to the endoplasmic reticulum is increased in ras- and abl-transformed NIH-3T3 cells that express significantly reduced levels of caveolin and few caveolae.	lauric acid	133-136	autocrine motility factor receptor	Mus musculus	73-78
12161174-1	2002	Cytochrome P450 (CYP)-dependent oxidation of lauric acid, p-nitrophenol and ethanol by microsomal fractions of kidney were studied in control rats and in animals given either ethanol, red wine, or alcohol-free red wine for 10 weeks.	lauric acid	45-56	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-15
12161174-1	2002	Cytochrome P450 (CYP)-dependent oxidation of lauric acid, p-nitrophenol and ethanol by microsomal fractions of kidney were studied in control rats and in animals given either ethanol, red wine, or alcohol-free red wine for 10 weeks.	lauric acid	45-56	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	17-20
12001171-1	2002	A kinetic model derived from the ping-pong bi-bi reversible mechanism is proposed to described the acylation of glucose by lauric acid in 2-methyl 2-butanol mediated by Candida antarctica lipase at 60 degrees C. The model accounts for the effect of all four compounds in the reaction mixture, namely lauric acid, glucose, water, and lauroyl glucose ester.	lauric acid	123-134	PAN0_003d1715	Moesziomyces antarcticus	188-194
12001171-1	2002	A kinetic model derived from the ping-pong bi-bi reversible mechanism is proposed to described the acylation of glucose by lauric acid in 2-methyl 2-butanol mediated by Candida antarctica lipase at 60 degrees C. The model accounts for the effect of all four compounds in the reaction mixture, namely lauric acid, glucose, water, and lauroyl glucose ester.	lauric acid	300-311	PAN0_003d1715	Moesziomyces antarcticus	188-194
15618652-9	2002	The activities of lauric acid 12-hydroxylation (a marker for Cyp4a) and aniline p-hydroxylation (a marker for Cyp2e1) in liver microsomes were increased 1.4- to 1.9-fold in female jvs/jvs-type mice.	lauric acid	18-29	cytochrome P450, family 4, subfamily a, polypeptide 10	Mus musculus	61-66
11840288-2	2002	We recently reported that the monocyclic monoterpene, perillyl alcohol (POH) selectively induces in Bcr/Abl transformed cells, G0/G1 arrest and apoptosis.	lauric acid	104-107	BCR activator of RhoGEF and GTPase	Homo sapiens	100-103
15618652-9	2002	The activities of lauric acid 12-hydroxylation (a marker for Cyp4a) and aniline p-hydroxylation (a marker for Cyp2e1) in liver microsomes were increased 1.4- to 1.9-fold in female jvs/jvs-type mice.	lauric acid	18-29	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	110-116
11455026-7	2001	The major effect of the Asp360Glu mutation was to increase the K(m) value relative to that of CYP2C9*1 for all three substrates: 12-fold higher for (S)-warfarin 7-hydroxylation, 5-fold higher for the 4"-hydroxylation of diclofenac, and 3-fold higher for the omega-1 hydroxylation of lauric acid.	lauric acid	283-294	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	94-100
11038153-4	2000	Homogenates of Sf9 cells expressing the CYP2K1 enzyme and LMC2 both catalyzed the hydroxylation of lauric acid and the epoxidation of AFB1 in the presence of rat NADPH-cytochrome P450 reductase.	lauric acid	99-110	cytochrome p450 oxidoreductase	Rattus norvegicus	162-193
11093148-3	2000	We demonstrated here that it was identical to p62Dok, a docking protein highly phosphorylated in human chronic myelogenous leukemia cells and in murine abl-transformed B cells.	lauric acid	152-155	docking protein 1	Homo sapiens	46-52
10593594-7	1999	Therefore, lauric acid (omega-1)-hydroxylation along with 4-nitrophenol hydroxylation can be used as a specific and sensitive method to measure the level of CYP2E1 induction in humans and various animals.	lauric acid	11-22	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	157-163
10993158-9	2000	The recombinant yeast microsomes containing CYP78A1 and yeast P450 reductase were found to catalyze 12-monooxygenation of lauric acid.	lauric acid	122-133	cytochrome P450 78A1	Zea mays	44-51
10825000-6	2000	The human RIN1 gene was isolated as an RAS interaction/interference protein in a genetic selection in yeast and has been described as a putative effector of both the RAS and ABL oncogenes.	lauric acid	174-177	Ras and Rab interactor 1	Homo sapiens	10-14
10648600-0	2000	Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.	lauric acid	92-95	interferon regulatory factor 8	Mus musculus	14-59
10648600-0	2000	Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.	lauric acid	92-95	interferon regulatory factor 8	Mus musculus	61-66
10648600-7	2000	We found that expression of the ICSBP protein was significantly decreased in Bcr-Abl-induced CML-like disease.	lauric acid	81-84	interferon regulatory factor 8	Mus musculus	32-37
10648600-8	2000	Forced coexpression of ICSBP inhibited the Bcr-Abl-induced colony formation of BM cells from 5-FU-treated mice in vitro and Bcr-Abl-induced CML-like disease in vivo.	lauric acid	47-50	interferon regulatory factor 8	Mus musculus	23-28
10648600-8	2000	Forced coexpression of ICSBP inhibited the Bcr-Abl-induced colony formation of BM cells from 5-FU-treated mice in vitro and Bcr-Abl-induced CML-like disease in vivo.	lauric acid	128-131	interferon regulatory factor 8	Mus musculus	23-28
10648600-10	2000	Overexpression of ICSBP consistently promotes rather than inhibits Bcr-Abl-induced B lymphoproliferation in a murine model where BM cells from non-5-FU-treated donors were used, indicating that ICSBP has a specific antitumor activity toward myeloid neoplasms.	lauric acid	71-74	interferon regulatory factor 8	Mus musculus	18-23
10620324-7	2000	The highest activity for lauric acid was obtained with CYP4A1 and CYP4A8, but for all the proteins the activity decreased with increasing fatty acid chain length.	lauric acid	25-36	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	55-61
10620324-7	2000	The highest activity for lauric acid was obtained with CYP4A1 and CYP4A8, but for all the proteins the activity decreased with increasing fatty acid chain length.	lauric acid	25-36	cytochrome P450, family 4, subfamily a, polypeptide 8	Rattus norvegicus	66-72
10961897-12	2000	Overexpression of wild-type p27 partially antagonizes Bcr-Abl-induced proliferation in Ba/F3 cells.	lauric acid	58-61	cyclin-dependent kinase inhibitor 1B	Mus musculus	28-31
9738460-8	1998	The stimulatory effect of CLA administration on the efficiency of the ethanolamine-specific PLBE reaction can be explained by elimination of lauric acid, a known inhibitor of de novo PE synthesis, during the course of omega-hydroxylation catalysed by CYP4A1, and by increased expression of the PLBE enzyme.	lauric acid	141-152	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	251-257
10348799-7	1999	Dealkylation of ethoxyresorufin and omega-hydroxylation of lauric acid activities from ob/ob and lean mice were not statistically different; however, leptin exposure significantly increased ethoxyresorufin activity in lean mice (14%) and decreased the activity in ob/ob mice (36%).	lauric acid	59-70	leptin	Mus musculus	150-156
10429660-5	1999	6,6"-Diester-trehaloses and 4,4"-diester-trehaloses of C8 to C12 fatty acids, 6,6"-diamide-trehaloses of C8 to C14 fatty acids, and n-dodecyl-beta-D-maltoside all inhibited TNF-alpha release in a dose-dependent manner.	lauric acid	61-76	tumor necrosis factor	Mus musculus	173-182
10024026-5	1999	Results of docking of a common substrate, lauric acid, into the binding site of both CYP4A11 and CYP102 and molecular dynamics simulations provided additional support for this hypothesis.	lauric acid	42-53	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	85-92
10024026-6	1999	Specifically, in the CYP4A11-lauric acid simulations, the omega hydrogens were closest to the ferryl oxygen most of the time.	lauric acid	29-40	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	21-28
10064003-8	1999	Plasminogen Activator Inhibitor (PAI-1) activity was higher on the palmitic acid compared with the oleic acid diet (difference between diets of 2.3 U/ml; P = 0.0098; 95% CI, 0.4 to 4.3 U/ml) and the lauric acid diet (difference between diets of 2.2 U/ml; P = 0.0123; 95% CI, 0.2 to 4.1 U/ml).	lauric acid	199-210	serpin family E member 1	Homo sapiens	33-38
10453996-5	1999	Cytochrome P450 4A1 modulates the cellular level of lauric acid, an inhibitor of phospholipid synthesis.	lauric acid	52-63	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	0-19
9886328-4	1998	Immunoblotting of p210BCR-ABL-positive platelets lysates with anti-CrkL antibody revealed a CrkL triplet consisting of one unphosphorylated and two phosphorylated forms of the protein.	lauric acid	26-29	CRK like proto-oncogene, adaptor protein	Homo sapiens	67-71
9886328-4	1998	Immunoblotting of p210BCR-ABL-positive platelets lysates with anti-CrkL antibody revealed a CrkL triplet consisting of one unphosphorylated and two phosphorylated forms of the protein.	lauric acid	26-29	CRK like proto-oncogene, adaptor protein	Homo sapiens	92-96
10362749-7	1999	CYP4A8 did not catalyze arachidonic or linoleic acid but did have a detectable lauric acid omega-hydroxylation activity.	lauric acid	79-90	cytochrome P450, family 4, subfamily a, polypeptide 8	Rattus norvegicus	0-6
10030391-2	1999	Serum CETP activity, measured as the rate of radiolabeled cholesteryl esters transferred from HDL toward serum apo B-containing lipoproteins, was higher with the palmitic acid diet (25.1+/-2.5%) than with the lauric acid (23.7+/-2.4%) and the oleic acid (24.0+/-2.7%) diets (P = 0.0028 and 0.0283, respectively).	lauric acid	209-220	cholesteryl ester transfer protein	Homo sapiens	6-10
10030391-3	1999	CETP mass concentrations, as measured with an enzyme-linked immunosorbent assay were increased after the lauric acid diet (2.57+/-0.63 mg/l) and the palmitic acid diet (2.49+/-0.64 mg/l) as compared with the oleic acid diet (2.34+/-0.45 mg/l) (P = 0.0035 and 0.0249, respectively).	lauric acid	105-116	cholesteryl ester transfer protein	Homo sapiens	0-4
10030391-4	1999	In contrast with CETP, serum PLTP activity, as measured as the rate of radiolabeled phosphatidylcholine transferred from liposomes toward serum HDL, was significantly higher with the lauric acid diet (23.5+/2.6%) than with the palmitic acid diet (22.5+/-2.5%) (P = 0.0013), while no significant differences were noted when comparing the saturated diets versus the oleic acid diet (23.0+/-2.3%).	lauric acid	183-194	phospholipid transfer protein	Homo sapiens	29-33
9782155-5	1998	Dodecanoic acid (C12) was most effective, producing up to a 5-fold increase in CCK secretion.	lauric acid	0-15	cholecystokinin	Homo sapiens	79-82
9737862-5	1998	Membrane preparations of human CYP4B1(Pro) and rabbit CYP4B1(Pro), but not the corresponding CYP4B1(Ser) variants, supported lauric acid hydroxylation preferentially at the omega-position.	lauric acid	125-136	cytochrome P450 family 4 subfamily B member 1	Homo sapiens	31-37
9737862-5	1998	Membrane preparations of human CYP4B1(Pro) and rabbit CYP4B1(Pro), but not the corresponding CYP4B1(Ser) variants, supported lauric acid hydroxylation preferentially at the omega-position.	lauric acid	125-136	cytochrome P450 4B1	Oryctolagus cuniculus	54-60
9737862-5	1998	Membrane preparations of human CYP4B1(Pro) and rabbit CYP4B1(Pro), but not the corresponding CYP4B1(Ser) variants, supported lauric acid hydroxylation preferentially at the omega-position.	lauric acid	125-136	cytochrome P450 4B1	Oryctolagus cuniculus	54-60
9722531-3	1998	The two proteins are spectroscopically indistinguishable, but wild-type CYP4A11 primarily catalyzes omega-hydroxylation, and the L131F mutant only omega-1 hydroxylation, of lauric acid.	lauric acid	173-184	cytochrome P450 family 4 subfamily A member 11	Homo sapiens	72-79
9540975-7	1998	This effect appeared to be specific for the class of anionic detergents because sodium dodecyl benzene sulfonate and sodium laurate also induced SKALP expression.	lauric acid	117-131	peptidase inhibitor 3	Homo sapiens	145-150
9643352-5	1998	After treatment of rats with ethanol or clofibrate, inducers of CYP2E1 and CYP4A, respectively, the hydroxylations of oleic acid were shown to be less inducible than those of lauric acid.	lauric acid	175-186	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	64-70
9581653-8	1998	Chemical inhibitions using CYP2E1 competitive inhibitors (such as chlorzoxazone and ethanol) led to a nonsignificant inhibition of the renal (omega-1)-hydroxylation of lauric acid.	lauric acid	168-179	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	27-33
9581653-10	1998	Immunoinhibitions specific to CYP2E1 significantly decreased the (omega-1)-hydroxylation of lauric acid in liver, but not in kidney microsomes, whereas the polyclonal anti-CYP4A1 antibody inhibited omega- and (omega-1)-hydroxylations of lauric acid in kidney microsomes.	lauric acid	92-103	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	30-36
9581653-10	1998	Immunoinhibitions specific to CYP2E1 significantly decreased the (omega-1)-hydroxylation of lauric acid in liver, but not in kidney microsomes, whereas the polyclonal anti-CYP4A1 antibody inhibited omega- and (omega-1)-hydroxylations of lauric acid in kidney microsomes.	lauric acid	92-103	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	172-178
9581653-10	1998	Immunoinhibitions specific to CYP2E1 significantly decreased the (omega-1)-hydroxylation of lauric acid in liver, but not in kidney microsomes, whereas the polyclonal anti-CYP4A1 antibody inhibited omega- and (omega-1)-hydroxylations of lauric acid in kidney microsomes.	lauric acid	237-248	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	30-36
9581653-10	1998	Immunoinhibitions specific to CYP2E1 significantly decreased the (omega-1)-hydroxylation of lauric acid in liver, but not in kidney microsomes, whereas the polyclonal anti-CYP4A1 antibody inhibited omega- and (omega-1)-hydroxylations of lauric acid in kidney microsomes.	lauric acid	237-248	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	172-178
9581653-12	1998	Lauric acid (omega-1)-hydroxylation, a highly specific probe for CYP2E1 in rat and human liver microsomes, is mediated by a CYP4A isoform in rat kidney microsomes.	lauric acid	0-11	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	65-71
9548900-3	1998	The permeability coefficient of LHRH was significantly (p < 0.05) greater through EtOH, lauric acid/EtOH, palmitic acid/EtOH, oleic acid/EtOH, linoleic acid/EtOH, and linolenic acid/EtOH treated epidermis than the control (untreated epidermis).	lauric acid	91-102	gonadotropin releasing hormone 1	Homo sapiens	32-36
9549343-13	1998	On the other hand, the intestinal absorption of thyrotropin releasing hormone (TRH), which is transported by a carrier-mediated process, was also enhanced by chemical modification with lauric acid.	lauric acid	185-196	thyrotropin releasing hormone	Homo sapiens	48-77
9566728-0	1998	Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid.	lauric acid	42-53	cytochrome P-450	Oryctolagus cuniculus	0-15
9495196-6	1998	Lauric acid (C(12:0); 3.2-6.5 mmol/L) caused an optimal effect--maximal anodal migration of alpha lipoproteins and clearing of the alpha1 region, facilitating inspection of that area for A1AT variants.	lauric acid	0-11	serpin family A member 1	Homo sapiens	187-191
9549343-13	1998	On the other hand, the intestinal absorption of thyrotropin releasing hormone (TRH), which is transported by a carrier-mediated process, was also enhanced by chemical modification with lauric acid.	lauric acid	185-196	thyrotropin releasing hormone	Homo sapiens	79-82
9701504-2	1998	This was accompanied by 3.4-fold activation of microsomal omega-hydroxylation of lauric acid by cytochrome P450 4A1 isoform (CYP4A1) and an increase in the protein content of this isoform in endoplasmic reticulum (ER) membranes.	lauric acid	81-92	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	96-115
9473656-4	1998	Rat DAO cDNA encodes 346 amino acid residues, indicating that rat DAO is an intermediate form between mouse DAO (345 amino acids) and DAOs (347 amino acids) of human, rabbit, and pig.	lauric acid	134-138	D-amino-acid oxidase	Rattus norvegicus	4-7
9473656-4	1998	Rat DAO cDNA encodes 346 amino acid residues, indicating that rat DAO is an intermediate form between mouse DAO (345 amino acids) and DAOs (347 amino acids) of human, rabbit, and pig.	lauric acid	134-138	D-amino-acid oxidase	Rattus norvegicus	66-69
9473656-4	1998	Rat DAO cDNA encodes 346 amino acid residues, indicating that rat DAO is an intermediate form between mouse DAO (345 amino acids) and DAOs (347 amino acids) of human, rabbit, and pig.	lauric acid	134-138	D-amino acid oxidase	Mus musculus	66-69
9701504-2	1998	This was accompanied by 3.4-fold activation of microsomal omega-hydroxylation of lauric acid by cytochrome P450 4A1 isoform (CYP4A1) and an increase in the protein content of this isoform in endoplasmic reticulum (ER) membranes.	lauric acid	81-92	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	125-131
9091577-2	1997	STAT3 expression in particular has been associated with Abl, Src, and HTLV-1 transformation of normal cells.	lauric acid	56-59	signal transducer and activator of transcription 3	Homo sapiens	0-5
9310344-5	1997	Lauric acid, a substrate of Cyp4b1, efficiently inhibited DCB bioactivation by renal and bladder microsomes of the mouse and by purified Cyp4b1.	lauric acid	0-11	cytochrome P450, family 4, subfamily b, polypeptide 1	Mus musculus	28-34
9310344-5	1997	Lauric acid, a substrate of Cyp4b1, efficiently inhibited DCB bioactivation by renal and bladder microsomes of the mouse and by purified Cyp4b1.	lauric acid	0-11	cytochrome P450, family 4, subfamily b, polypeptide 1	Mus musculus	137-143
9299232-5	1997	Sequence analysis identified a high degree of homology with the mouse sh3bp2 gene, which is abl-binding, suggesting that this gene is the human homologue.	lauric acid	92-95	SH3-domain binding protein 2	Mus musculus	70-76
9164261-5	1997	Lauric acid omega-1 hydroxidation by the liver microsomes in vitro was increased by ethanol and partially blocked by CYP2E1 inhibitors.	lauric acid	0-11	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	117-123
8811432-1	1996	The formation of (omega-1)-hydroxylauric acid from lauric acid (LA) can be used as an indicator of the activity of cytochrome P450 2E1 (CYP2E1) in rat and human liver microsomes.	lauric acid	34-45	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	115-134
8954571-7	1996	CYP4A2/OR membranes metabolized lauric acid at a high rate (7 and 5.5 nmol/min/nmol P450 in the presence and absence of b5, respectively).	lauric acid	32-43	cytochrome P450, family 4, subfamily a, polypeptide 2	Rattus norvegicus	0-6
8765103-0	1996	Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid.	lauric acid	139-150	thyrotropin releasing hormone	Rattus norvegicus	39-68
8765103-1	1996	The transport characteristics of thyrotropin-releasing hormone (TRH) and its chemically modified derivative with lauric acid (Lau-TRH) across the rat small or large intestine were estimated by means of an in vitro everted sac experiment.	lauric acid	113-124	thyrotropin releasing hormone	Rattus norvegicus	130-133
8765103-3	1996	The penetration of TRH across the upper small intestine was significantly increased by conjugation with lauric acid.	lauric acid	104-115	thyrotropin releasing hormone	Rattus norvegicus	19-22
8765103-8	1996	The binding amounts of TRH to the BBM were remarkably enhanced by the lauric acid conjugation; however, its binding was nonspecific.	lauric acid	70-81	thyrotropin releasing hormone	Rattus norvegicus	23-26
8837739-2	1996	To elucidate the chemical basis of this specificity we probed the active site of a CYP4A1 fusion protein (f4A1) with bulky and/ or rigid analogs of lauric acid, the optimum natural substrate for f4A1 and CYP4A1.	lauric acid	148-159	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	83-89
8811432-1	1996	The formation of (omega-1)-hydroxylauric acid from lauric acid (LA) can be used as an indicator of the activity of cytochrome P450 2E1 (CYP2E1) in rat and human liver microsomes.	lauric acid	34-45	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	136-142
8866826-10	1996	Human CYP2E1 had the highest lauric acid (omega-1)-hydroxylation activity and also had catalytic properties similar to those of rat CYP2E1.	lauric acid	29-40	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	6-12
8665954-8	1996	The binding seen with lauric acid PLA was not mediated by GPIIb/IIIa.	lauric acid	22-33	phospholipase A2 group IB	Homo sapiens	34-37
8649859-3	1996	These findings have led us to broaden our study of cbl"s involvement in abl-mediated tumorigenesis.	lauric acid	72-75	Casitas B-lineage lymphoma	Mus musculus	51-54
8649859-4	1996	Here we show by immunodepletion that cbl is the major 120-kD tyrosine phosphorylated protein in cells which express activated forms of the abl oncogene.	lauric acid	139-142	Casitas B-lineage lymphoma	Mus musculus	37-40
8615855-0	1995	Validation of the (omega-1)-hydroxylation of lauric acid as an in vitro substrate probe for human liver CYP2E1.	lauric acid	45-56	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	104-110
8825670-2	1996	The PIV and TCA treatments resulted in a similar and selective induction (2-3 times) of peroxisomal palmitoyl-CoA oxidase and the cytochrome P-450 4A dependent microsomal (omega)- and (omega-1)-lauric acid activities, both in liver and kidney.	lauric acid	194-205	acyl-CoA oxidase 1	Rattus norvegicus	100-121
8615855-8	1995	Taken together, these results suggest that CYP2E1 is involved in the (omega-1)-hydroxylation of lauric acid in human liver microsomes, and omega-hydroxylation is mediated by another enzyme.	lauric acid	96-107	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	43-49
8605977-4	1996	These results together with the observed competition (i.e. prevention of photolabelling) of various UcP anionic substrates with [3H]AzHA and its dodecanoic acid analogue, suggest the existence of the specific fatty acid binding site on UcP identical with the anion channel or anion translocating site.	lauric acid	145-160	uncoupling protein 1	Homo sapiens	100-103
8605977-4	1996	These results together with the observed competition (i.e. prevention of photolabelling) of various UcP anionic substrates with [3H]AzHA and its dodecanoic acid analogue, suggest the existence of the specific fatty acid binding site on UcP identical with the anion channel or anion translocating site.	lauric acid	145-160	uncoupling protein 1	Homo sapiens	236-239
8615855-9	1995	Finally, the use of yeasts and mammalian cells genetically engineered for expression of 9 human P450s demonstrated that CYP2E1 was the one enzyme involved in the (omega-1)-hydroxylation of lauric acid.	lauric acid	189-200	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	120-126
8615855-1	1995	The (omega-1)-hydroxylation of lauric acid (11-OH-LA), a model substrate of fatty acids, was previously shown to be due to CYP2E1 in rat liver microsomes.	lauric acid	31-42	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	123-129
8615855-4	1995	The (omega-1)-hydroxylation of lauric acid was inhibited by ethanol (Ki = 3.5 mM), acetone (IC50 = 10 mM) dimethylsulfoxide, chlorzoxazone (competitive inhibitors of CYP2E1), diethyldithiocarbamate, and diallylsulfide (both selective mechanism-based inactivators of CYP2E1).	lauric acid	31-42	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	166-172
8615855-4	1995	The (omega-1)-hydroxylation of lauric acid was inhibited by ethanol (Ki = 3.5 mM), acetone (IC50 = 10 mM) dimethylsulfoxide, chlorzoxazone (competitive inhibitors of CYP2E1), diethyldithiocarbamate, and diallylsulfide (both selective mechanism-based inactivators of CYP2E1).	lauric acid	31-42	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	266-272
7872779-0	1995	Biochemical characterization of lauric acid omega-hydroxylation by a CYP4A1/NADPH-cytochrome P450 reductase fusion protein.	lauric acid	32-43	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	69-75
7649186-8	1995	The purified cytochrome P-450 fraction catalysed in addition omega- and omega-1 hydroxylation of lauric acid and 6 alpha-hydroxylation of 3 alpha-hydroxy-5 beta-cholanoic acid (lithocholic acid).	lauric acid	97-108	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	13-29
7547928-5	1995	Furthermore, affinities of L-FABP for NBD-fatty acid probes were NBD-stearic acid > NBD-lauric acid >>> NBD-hexanoic acid, NBD-acetic acid.	lauric acid	91-102	fatty acid binding protein 1	Homo sapiens	27-33
8529824-9	1995	Cytochrome P450 4A1 increased in both species at doses of 25 mg/kg or greater and correlated with increased lauric acid hydroxylation.	lauric acid	108-119	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	0-19
7872779-1	1995	The binding and hydroxylation of lauric acid by a genetically engineered and expressed fusion protein comprised of an N-truncated form of rat CYP4A1 linked to an N-truncated form of rat NADPH cytochrome P450 oxidoreductase (OR) (constructed by Fisher et al., (1992) Proc.	lauric acid	33-44	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	142-148
7872779-8	1995	(omega-1)-Hydroxylation of lauric acid was barely detectable (omega/(omega-1) = 135) with f4A1 or with reconstituted CYP4A1, but it accounted for up to 50% of total products formed by microsomes from clofibrate-induced rats.	lauric acid	27-38	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	117-123
7696540-0	1994	Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes.	lauric acid	0-11	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	71-96
7970713-11	1994	RT-PCR analysis on colonies of abl-transduced cells from 2-3 day cultures indicated a reduction of IL-4 and IL-1 alpha in these cells, and they entered cell division sooner.	lauric acid	31-34	interleukin 4	Mus musculus	99-103
7970713-11	1994	RT-PCR analysis on colonies of abl-transduced cells from 2-3 day cultures indicated a reduction of IL-4 and IL-1 alpha in these cells, and they entered cell division sooner.	lauric acid	31-34	interleukin 1 alpha	Mus musculus	108-118
9372837-8	1995	Similarly, the rate and pattern of CYP enzyme-mediated hydroxylation toward testosterone, 17 beta-estradiol, corticosterone, and lauric acid were greatly altered by nongenotoxic carcinogen treatment.	lauric acid	129-140	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	35-38
7696540-1	1994	In vitro techniques have been utilized to investigate the microsomal enzymes involved in the metabolism of lauric acid and to establish conditions in which it can be used as a model substrate for both cytochrome P450 4A and cytochrome P450 2E1 in human liver microsomes.	lauric acid	107-118	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	224-243
8013058-1	1994	The effect of lauric acid (LA) and lysolauroyllecithin (LLL) on the hydrolysis of lipid in monolayer by phospholipase A2 from Bee venom was studied.	lauric acid	14-25	phospholipase A2 group IB	Homo sapiens	104-120
8167335-4	1994	Only low levels of IL-3R beta were observed in the two v-abl-transformed derivative cell lines examined, which no longer required IL-3 for growth.	lauric acid	57-60	colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)	Mus musculus	19-29
8167335-4	1994	Only low levels of IL-3R beta were observed in the two v-abl-transformed derivative cell lines examined, which no longer required IL-3 for growth.	lauric acid	57-60	interleukin 3	Mus musculus	19-23
7765813-2	1994	Dodecylamine, dodecanal, dodecanoic acid and acetic acid also supported growth of Pseudomonas MA3.	lauric acid	25-40	PNMA family member 3	Homo sapiens	94-97
8089110-2	1994	To identify other amino acid substitutions that alter the activity of TEM-1 toward extended-spectrum cephalosporins, a random library was constructed that contained all possible amino acid substitutions over the 3-residue window of 238-241 (ABL numbering).	lauric acid	241-244	CD248 molecule	Homo sapiens	70-75
8093035-0	1994	Evidence that cytochrome P450 2E1 is involved in the (omega-1)-hydroxylation of lauric acid in rat liver microsomes.	lauric acid	80-91	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	14-33
8093035-6	1994	These results suggest that the (omega-1)-hydroxylation of lauric acid is mediated principally by the CYP2E1 enzyme in rat liver microsomes.	lauric acid	58-69	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	101-107
7852283-5	1994	Both an immunoprecipitation study and Ouchterlony"s double diffusion test involving antiserum against the purified DAO showed that the immunological properties of the DAOs from rat small intestine, thymus, and placenta were identical.	lauric acid	167-171	amine oxidase, copper containing 1	Rattus norvegicus	115-118
8068495-2	1994	rac-2-PPA (250 mg/kg/day ip x 3) was shown to be an hepatic peroxisomal proliferator in male Sprague-Dawley rats on the basis of increases in microsomal cytochrome P-450 content and lauric acid hydroxylation and hepatic CN(-)-insensitive palmitoyl-CoA oxidation, a peroxisomal marker activity, while electron microscopy revealed a rise in the peroxisome/mitochondria ratio in hepatocytes.	lauric acid	182-193	Rac family small GTPase 2	Rattus norvegicus	0-9
8119916-9	1994	p93c-Fes could contribute to the transforming activity of the abl oncogenes.	lauric acid	62-65	FES proto-oncogene, tyrosine kinase	Homo sapiens	0-8
8218420-3	1993	NAK encodes a candidate protein kinase that is similar to the oncogenes met and abl.	lauric acid	80-83	Protein kinase superfamily protein	Arabidopsis thaliana	0-3
8437102-9	1993	Lauric acid hydroxylation increased 2-fold in arthritic rat and was further potentiated by IL-1.	lauric acid	0-11	interleukin 1 beta	Homo sapiens	91-95
7679927-4	1993	A solubilized preparation of the enzyme reconstituted with cytochrome P-450 reductase catalyzed the omega-hydroxylation of lauric acid, palmitic acid, and arachidonic acid with turnover numbers of 9.8, 2.2 and 0.55 min-1, respectively.	lauric acid	123-134	CD59 molecule (CD59 blood group)	Homo sapiens	215-220
8216351-3	1993	Consistent with these conclusions, both trimer and tetramer increased the hydroxylation of lauric acid indicating that the CTFEs were inducers of the CYP4A subfamily, a conclusion further supported by substantial increases in the steady-state levels of the cognate CYP4A1 mRNA as determined by northern blotting.	lauric acid	91-102	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	265-271
7678807-5	1993	Moreover, amino acid substitutions around phosphotyrosine in the peptides src(412-418), src(414-418) and abl-(390-397) deeply influence the dephosphorylation efficiency.	lauric acid	105-108	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	74-77
16653069-0	1992	Cytochrome p-450-dependent hydroxylation of lauric Acid at the subterminal position and oxidation of unsaturated analogs in wheat microsomes.	lauric acid	44-55	cytochrome P450 709B1	Triticum aestivum	0-16
1457045-6	1992	Three of the five additional CYP52 genes could be successfully expressed in Saccharomyces cerevisiae and display different substrate specificities in in vitro assays with model substrates: alk2 and alk3 exhibit a strong preference for hexadecane, while alk4 and alk5 preferentially hydroxylate lauric acid.	lauric acid	294-305	protein kinase ALK2	Saccharomyces cerevisiae S288C	189-193
1662512-6	1991	This was confirmed by the observations that (1) lauric acid hydroxylation was inhibited by 0.02% Tween 20 or Tween 80 and 25 microM capric or myristic acids, whereas omega-MMEN hydroxylation was not, (2) omega-MMEN hydroxylation was inhibited by ketoconazole, cholesterol and acetone, whereas lauric acid hydroxylation was not, and (3) CYP4A1 and CYP4A3 expressed in Hep G2 cells did not catalyze MMEN hydroxylation.	lauric acid	48-59	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	336-342
1360521-0	1992	Improvement of intestinal absorption of thyrotropin-releasing hormone by chemical modification with lauric acid.	lauric acid	100-111	thyrotropin releasing hormone	Rattus norvegicus	40-69
1593871-7	1992	Thus, while adipic acid (C6) had no effect, Caprylic acid (C8) had a minimal effect that was not statistically significant, but capric acid (C10) and lauric acid had very potent effects that were of the same magnitude to the effect of linoleate on insulin secretion.	lauric acid	150-161	insulin	Homo sapiens	248-255
1593871-8	1992	When insulin output was assessed as the mean integrated area under the curve during a 20-min perifusion, 5 mM lauric acid enhanced insulin secretion from a basal 7351 +/- 666 pg to 15,756 +/- 1680 pg (P less than 0.01, n = 5).	lauric acid	110-121	insulin	Homo sapiens	5-12
1293309-7	1992	Perfluorooctanoic acid also caused a persistent effect in omega hydroxylation of lauric acid (cytochrome P-452).	lauric acid	81-92	cytochrome P450, family 4, subfamily a, polypeptide 10	Mus musculus	94-110
1662512-6	1991	This was confirmed by the observations that (1) lauric acid hydroxylation was inhibited by 0.02% Tween 20 or Tween 80 and 25 microM capric or myristic acids, whereas omega-MMEN hydroxylation was not, (2) omega-MMEN hydroxylation was inhibited by ketoconazole, cholesterol and acetone, whereas lauric acid hydroxylation was not, and (3) CYP4A1 and CYP4A3 expressed in Hep G2 cells did not catalyze MMEN hydroxylation.	lauric acid	48-59	cytochrome P450, family 4, subfamily a, polypeptide 3	Rattus norvegicus	347-353
1834341-3	1991	Also lauric acid inhibited cell growth while its blocking effect on the Ca2+ signal was weaker than that of myristic acid.	lauric acid	5-16	carbonic anhydrase 2	Homo sapiens	72-75
1807160-4	1991	Individual C-10 through C-14 alkyl sulfates, C-11 through C-14 alkyl sulfonates, sodium N-lauroyl-N-methyl-taurine, N-lauroylsarcosine, sodium laurate, or benzyldimethyl-n-hexadecylammonium chloride were substituted for SDS in equilibration buffer, gel buffer, and upper running buffer.	lauric acid	136-150	chromosome 12 open reading frame 57	Homo sapiens	11-15
2043673-8	1991	The level of P450 K-5 (fatty acid omega-hydroxylase) in SHR was 50% higher than that in WKY and the difference reflected the increase in lauric acid omega- and (omega-1)-hydroxylation activities of the renal microsomes of SHR.	lauric acid	137-148	cytochrome P450, family 4, subfamily a, polypeptide 2	Rattus norvegicus	19-51
1866381-1	1991	Thyrotropin-releasing hormone (TRH) was derivatized by chemical attachment of lauric acid to the N-terminal pyroglutamyl group.	lauric acid	78-89	thyrotropin releasing hormone	Homo sapiens	0-29
1866381-1	1991	Thyrotropin-releasing hormone (TRH) was derivatized by chemical attachment of lauric acid to the N-terminal pyroglutamyl group.	lauric acid	78-89	thyrotropin releasing hormone	Homo sapiens	31-34
1766258-1	1991	We have examined the expression of the protein tyrosine kinase (PTK) encoding oncogenes fes and abl in normal and malignant human myeloid cells in immunoblotting experiments.	lauric acid	96-99	EPH receptor A8	Homo sapiens	64-67
1704675-6	1990	When individual constituents of cholesteatoma debris, i.e. keratin, cholesterol, lauric acid and LPS, were added to the cultured monocytes at concentrations equivalent to those in the debris, significant production of TNF was observed only with the keratin and LPS.	lauric acid	81-92	tumor necrosis factor	Homo sapiens	218-221
33971268-9	2021	Moreover, effects of intra-VTA infusion of lauric acid (a saturated fatty acid with 12 carbon) on food reward were abolished in mice lacking TLR4 in DA neurons.	lauric acid	43-54	toll-like receptor 4	Mus musculus	141-145
2229008-5	1990	P450 L-2 had high lauric acid omega- and (omega-1)-hydroxylation activities, but low prostaglandin A1 omega- and (omega-1)-hydroxylation activities.	lauric acid	18-29	cytochrome P450, family 4, subfamily b, polypeptide 1	Rattus norvegicus	6-8
2141005-0	1990	Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogenate and lauric acid.	lauric acid	124-135	tumor necrosis factor	Homo sapiens	0-21
2317528-9	1990	Lauric acid was also hydroxylated by P450 UT-1, UT-2, PB-1, PB-2, MC-1, IF-3 (P-450a) and DM, at the (omega - 1)-position only.	lauric acid	0-11	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	48-52
2317528-9	1990	Lauric acid was also hydroxylated by P450 UT-1, UT-2, PB-1, PB-2, MC-1, IF-3 (P-450a) and DM, at the (omega - 1)-position only.	lauric acid	0-11	cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1	Rattus norvegicus	54-58
2306108-8	1990	Lauric acid was metabolized efficiently by all of these forms in the presence of cytochrome b5.	lauric acid	0-11	cytochrome b5 type A	Homo sapiens	81-94
2306108-10	1990	P450 K-2 hydroxylated lauric acid only at the (omega-1)-position, not at the omega-position.	lauric acid	22-33	RBPJ pseudogene 3	Homo sapiens	5-8
2306108-11	1990	P450 K-4 and K-5 hydroxylated lauric acid at both the omega- and (omega-1)-positions.	lauric acid	30-41	keratin 4	Homo sapiens	5-8
2306108-11	1990	P450 K-4 and K-5 hydroxylated lauric acid at both the omega- and (omega-1)-positions.	lauric acid	30-41	keratin 5	Homo sapiens	13-16
2306108-16	1990	P450 HK had high lauric acid omega- and (omega-1)-hydroxylation activities in the presence of cytochrome b5, especially omega-hydroxylation.	lauric acid	17-28	cytochrome b5 type A	Homo sapiens	94-107
2169238-6	1990	The preparation also catalysed the 25-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha-diol at a rate of 1000 pmol.min-1.nmol of cytochrome P-450-1 and omega-1 hydroxylation of lauric acid at a rate of 200 pmol.min-1.nmol of cytochrome P-450-1.	lauric acid	179-190	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	131-147
2169238-6	1990	The preparation also catalysed the 25-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha-diol at a rate of 1000 pmol.min-1.nmol of cytochrome P-450-1 and omega-1 hydroxylation of lauric acid at a rate of 200 pmol.min-1.nmol of cytochrome P-450-1.	lauric acid	179-190	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	227-243
2165389-1	1990	The uptake and intracellular metabolism of 4-(1-pyrene)butanoic acid (P4), 10-(1-pyrene)decanoic acid (P10) and 12-(1-pyrene)dodecanoic acid (P12) were investigated in cultured lymphoid cell lines from normal individuals and from a patient with multisystemic lipid storage myopathy (MLSM).	lauric acid	125-140	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	142-145
2141005-1	1990	Recombinant human tumor necrosis factor (rh TNF) when administered intravenously together with the phospholipase C inhibitor tricyclodecan-9-yl-xanthogenate (D609) and lauric acid (C12), leads to the partial regression of various human tumor transplants in athymic mice.	lauric acid	168-179	tumor necrosis factor	Homo sapiens	18-39
35466692-11	2022	CB metabolites, such as lauric acid, a medium chain FA which may improve insulin sensitivity, were associated with neonatal adiposity differently between offspring of women with and without obesity.	lauric acid	24-35	insulin	Homo sapiens	73-80
34506767-0	2021	Lauric acid alleviates deoxynivalenol-induced intestinal stem cell damage by potentiating the Akt/mTORC1/S6K1 signaling axis.	lauric acid	0-11	thymoma viral proto-oncogene 1	Mus musculus	94-97
34506767-0	2021	Lauric acid alleviates deoxynivalenol-induced intestinal stem cell damage by potentiating the Akt/mTORC1/S6K1 signaling axis.	lauric acid	0-11	CREB regulated transcription coactivator 1	Mus musculus	98-104
34506767-0	2021	Lauric acid alleviates deoxynivalenol-induced intestinal stem cell damage by potentiating the Akt/mTORC1/S6K1 signaling axis.	lauric acid	0-11	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	105-109
34321852-10	2021	However, the serum level of MUC2 in CRC patients was higher than that in normal controls, and was positively associated with serum levels of human DAO (chi 2 = 3.957, P < 0.05) and D-LAC (chi 2 = 7.236, P < 0.05), which are the biomarkers of the functional status of the intestinal mucosal barrier.	lauric acid	147-150	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	28-32
32796898-6	2020	We identified that uniform-phase SLB formation occurred independently of total lipid concentration when the ratio of long-chain phospholipid to capric acid molecules ("q-ratio") was 0.25 or 2.5, which is superior to past results with lauric acid- and monocaprin-containing bicelles in which cases lipid concentration-dependent behavior was observed.	lauric acid	234-245	intraflagellar transport 172	Homo sapiens	33-36
34666046-6	2022	In this work, we assessed oleic and lauric acid for their impact on particle formation as each represents the main hydrolysis product of PS80 or PS20, respectively.	lauric acid	36-47	WAP four-disulfide core domain 1	Homo sapiens	145-149
34245824-10	2021	LU treatment attenuated ERK and JNK phosphorylation, MCP-1 secretion and NO accumulation but increased ROS production during infection, and similar pattern with MALT1 protein expression.	lauric acid	0-2	mast cell protease 1	Mus musculus	53-58
35499234-0	2022	Lauric acid impairs insulin-induced Akt phosphorylation by upregulating SELENOP expression via HNF4alpha induction.	lauric acid	0-11	insulin	Homo sapiens	20-27
35597806-7	2022	Surprisingly, p27-Y88F mice succumbed to premature v-ABL induced leukemia/lymphoma compared to p27 wild type animals.	lauric acid	53-56	cyclin-dependent kinase inhibitor 1B	Mus musculus	14-17
35499234-0	2022	Lauric acid impairs insulin-induced Akt phosphorylation by upregulating SELENOP expression via HNF4alpha induction.	lauric acid	0-11	AKT serine/threonine kinase 1	Homo sapiens	36-39
35499234-0	2022	Lauric acid impairs insulin-induced Akt phosphorylation by upregulating SELENOP expression via HNF4alpha induction.	lauric acid	0-11	selenoprotein P	Homo sapiens	72-79
35499234-0	2022	Lauric acid impairs insulin-induced Akt phosphorylation by upregulating SELENOP expression via HNF4alpha induction.	lauric acid	0-11	hepatocyte nuclear factor 4 alpha	Homo sapiens	95-104
35499234-5	2022	Here we report novel mechanisms that underlie the lauric acid-mediated Selenop gene regulation in hepatocytes.	lauric acid	50-61	selenoprotein P	Homo sapiens	71-78
35499234-6	2022	Lauric acid upregulated Selenop expression in Hepa1-6 hepatocytes and mice liver.	lauric acid	0-11	selenoprotein P	Mus musculus	24-31
35499234-8	2022	A chromatin immunoprecipitation (ChIP) assay showed that lauric acid increased the binding of HNF4alpha to the SELENOP promoter.	lauric acid	57-68	hepatocyte nuclear factor 4 alpha	Homo sapiens	94-103
35499234-8	2022	A chromatin immunoprecipitation (ChIP) assay showed that lauric acid increased the binding of HNF4alpha to the SELENOP promoter.	lauric acid	57-68	selenoprotein P	Mus musculus	111-118
35499234-9	2022	The knockdown of Hnf4alpha using siRNA canceled the upregulation of lauric acid-induced Selenop.	lauric acid	68-79	hepatocyte nuclear factor 4 alpha	Homo sapiens	17-26
35499234-9	2022	The knockdown of Hnf4alpha using siRNA canceled the upregulation of lauric acid-induced Selenop.	lauric acid	68-79	selenoprotein P	Mus musculus	88-95
35499234-10	2022	Thus, the lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4alpha or Selenop.	lauric acid	10-21	AKT serine/threonine kinase 1	Homo sapiens	44-47
35499234-10	2022	Thus, the lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4alpha or Selenop.	lauric acid	10-21	insulin	Homo sapiens	81-88
35499234-10	2022	Thus, the lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4alpha or Selenop.	lauric acid	10-21	hepatocyte nuclear factor 4 alpha	Homo sapiens	128-137
35499234-10	2022	Thus, the lauric acid-induced impairment of Akt phosphorylation brought about by insulin was rescued by the knockdown of either Hnf4alpha or Selenop.	lauric acid	10-21	selenoprotein P	Mus musculus	141-148
35212699-4	2022	The BIF peptide, lauric acid-FFVLK-HSDVHK (LAFH) can self-assemble into nanoparticles (NPs) in solution and further transform into a fibrous structure, the fibrillogenesis of which could be accelerated by the addition of Ca2+.	lauric acid	17-28	carbonic anhydrase 2	Homo sapiens	221-224
2621418-3	1989	The relative contribution of various PC species towards LCAT reaction in ABL plasma was significantly different from that found in normal plasma.	lauric acid	73-76	lecithin-cholesterol acyltransferase	Homo sapiens	56-60
2621418-7	1989	Incubation of ABL plasma in the presence of normal VLDL or LDL resulted in normalization of its molecular species composition and in the stimulation of its LCAT activity.	lauric acid	14-17	lecithin-cholesterol acyltransferase	Homo sapiens	156-160
2776771-3	1989	There was a marked compound dependence on induction of both cytochrome P-450-IVA1-dependent omega-hydroxylation of lauric acid and enzymes of the peroxisomal fatty acid beta-oxidation pathway (measured as cyanide-insensitive palmitoyl-CoA oxidation and enoyl-CoA hydratase).	lauric acid	115-126	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	60-81
2776771-4	1989	Cytochrome P-450 IVA1 (or a very closely related isoenzyme in the same gene family) was a major constitutive haemoprotein in rat kidney microsomes and actively supported the omega-hydroxylation of lauric acid.	lauric acid	197-208	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	0-21
2776771-6	1989	By using a cDNA probe to the cytochrome P-450 IVA1 gene in Northern blot analysis, we have shown that increased renal and hepatic omega-hydroxylation of lauric acid, after treatment with peroxisome proliferators is a consequences of a substantial increase in the mRNA coding for this haemoprotein.	lauric acid	153-164	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	29-50
2504167-0	1989	Omega- and (omega-1)-hydroxylation of lauric acid and arachidonic acid by rat renal cytochrome P-450.	lauric acid	38-49	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	84-100
2650633-8	1989	Identification of the Ph1 acute lymphoblastic leukemia (ALL) has become possible by studying abl oncogene in Ph1 positive ALL.	lauric acid	93-96	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	22-25
2650633-8	1989	Identification of the Ph1 acute lymphoblastic leukemia (ALL) has become possible by studying abl oncogene in Ph1 positive ALL.	lauric acid	93-96	alanine--glyoxylate and serine--pyruvate aminotransferase	Homo sapiens	109-112
2761351-10	1989	From our results and those of other authors, it is suggested that lauric acid is a good substrate for sn-glycero-3-phosphate acyltransferase and diacylglycerol acyltransferase in rat adipose tissue.	lauric acid	66-77	diacylglycerol O-acyltransferase 1	Rattus norvegicus	145-175
3198593-3	1988	In contrast, cytochrome P-450b oxidizes lauric acid much more slowly (0.5 nmol/nmol P-450/min) to an 8:1 mixture of the same metabolites.	lauric acid	40-51	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	13-30
2504167-2	1989	P450 K-4 and K-5 had high omega- and (omega-1)-hydroxylation activities toward lauric acid.	lauric acid	79-90	keratin 4	Rattus norvegicus	5-8
2504167-2	1989	P450 K-4 and K-5 had high omega- and (omega-1)-hydroxylation activities toward lauric acid.	lauric acid	79-90	keratin 5	Rattus norvegicus	13-16
2847946-3	1988	To metabolize extracellular superoxide radicals effectively at or near cell membranes, we synthesized amphipathic superoxide dismutase (SOD) derivatives (AC-SOD) by covalently linking hydrophobic fatty acids with different chain lengths, such as caprylic acid, capric acid, lauric acid and myristic acid, to the lysyl amino groups of the enzyme.	lauric acid	274-285	superoxide dismutase 1	Homo sapiens	114-134
2847946-3	1988	To metabolize extracellular superoxide radicals effectively at or near cell membranes, we synthesized amphipathic superoxide dismutase (SOD) derivatives (AC-SOD) by covalently linking hydrophobic fatty acids with different chain lengths, such as caprylic acid, capric acid, lauric acid and myristic acid, to the lysyl amino groups of the enzyme.	lauric acid	274-285	superoxide dismutase 1	Homo sapiens	136-139
2502468-6	1989	Lauric acid hydroxylation and hydratation of trans-stilbene oxide by the cytosolic epoxide hydrolase were markedly increased by the arylcarboxylic acids (fenofibrate, bezafibrate and ciprofibrate).	lauric acid	0-11	epoxide hydrolase 2	Rattus norvegicus	73-100
2977757-8	1988	RS-1 and RS-2 are teicoplanins having 10-methyl-undecanoic acid and n-dodecanoic acid, respectively as fatty acid chains.	lauric acid	68-85	retinoschisin 1	Homo sapiens	0-4
3365259-2	1988	In this study, it has been observed that the nodules show a large decrease in an additional cytochrome P-450, cytochrome P-452, which is very active in the hydroxylation of lauric acid at C-11 and C-12.	lauric acid	173-184	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	110-126
3133648-6	1988	Lauric acid is a substrate known to be metabolized by a renal cytochrome P-450 to 11 and 12-hydroxylated products.	lauric acid	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	62-78
3298457-6	1987	Conversely, LTA, as well as lauric acid and oleic acid, blocked the binding of the same monoclonal antibodies to fibronectin.	lauric acid	28-39	fibronectin 1	Homo sapiens	113-124
3801020-3	1986	P-450K-5 catalyzed the omega- and (omega-1)-hydroxylation of lauric acid, but was inefficient in the N-demethylation of benzphetamine and the O-dealkylation of 7-ethoxycoumarine.	lauric acid	61-72	cytochrome P450, family 4, subfamily a, polypeptide 2	Rattus norvegicus	0-8
2879570-3	1987	Lauric acid was detected following hydroxylamine treatment of the enzyme, suggesting the occurrence of a fatty acid-type, covalent, posttranslational modification of transglutaminase.	lauric acid	0-11	protein-glutamine gamma-glutamyltransferase 2	Cavia porcellus	166-182
3107980-0	1987	cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemia.	lauric acid	63-66	BCR activator of RhoGEF and GTPase	Homo sapiens	24-27
3758926-8	1986	While in the MC-treated patients there was some positive correlation between the insulin dose and the level of Abl no significant correlation was found between the diabetes control and insulin antibody titers in both groups of patients.	lauric acid	111-114	insulin	Homo sapiens	81-88
4086944-3	1985	In intestine and liver, however, large amounts of rac-1-O-[1"-14C]dodecylglycerol were catabolized by oxidative cleavage of the ether bond followed by degradation of the radioactive cleavage product, i.e., lauric acid, to water-soluble metabolites that were excreted in the urine at a fast rate.	lauric acid	206-217	Rac family small GTPase 1	Mus musculus	50-55
3964299-1	1986	Clofibrate, an antilipidemic drug that acts by a still obscure mechanism, is known to specifically increase up to 30-fold the activity of the hepatic cytochrome P-450 isozyme that omega-hydroxlates lauric acid.	lauric acid	198-209	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	150-166
3948866-2	1986	Multiple binding of laurate (n-dodecanoate) to human serum albumin was studied by a kinetic dialysis method.	lauric acid	29-42	albumin	Homo sapiens	53-66
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	lauric acid	36-47	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
3931693-10	1985	A close linkage was established between bilirubin UDPglucuronosyltransferase induction and that of cytochrome P-452, as shown by enhanced omega-oxidation of lauric acid.	lauric acid	157-168	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	99-115
3929789-0	1985	Immunochemical study on the contribution of hypolipidaemic-induced cytochrome P-452 to the metabolism of lauric acid and arachidonic acid.	lauric acid	105-116	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	67-83
3929789-2	1985	All of the hypolipidaemic drugs tested significantly induced the hydroxylation of lauric acid and, furthermore, this was accompanied by a concomitant 3-fold induction of a specific isoenzyme of cytochrome P-450 (termed cytochrome P-452) as determined by a single radial immunodiffusion technique.	lauric acid	82-93	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	219-235
3929789-5	1985	Cytochrome P-452 plays a significant role in the hydroxylation of lauric acid as evidenced by inhibition of hydroxylase activity in the presence of an anti-P-452 IgG fraction.	lauric acid	66-77	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	0-16
6706995-1	1984	The terminal acetylenic analogue of lauric acid, 11-dodecynoic acid (11-DDYA), specifically inactivates hepatic cytochrome P-450 enzymes that catalyze omega- and omega-1-hydroxylation of lauric acid.	lauric acid	187-198	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	112-128
6711016-7	1984	The results indicate that hypolipidaemic agents which stimulate hepatic peroxisomal enzyme activities also induce novel form(s) of cytochrome P-450 with high specificity towards lauric acid hydroxylation.	lauric acid	178-189	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	131-147
6788761-4	1981	Kinetic measurements established Ki = 1.5 X 10(-3) M for dodecanoic acid (lauric acid) inhibition of lipoxygenase when the substrate is linoleic acid (Km = 2.6 X 10(-5) M).	lauric acid	57-72	linoleate 9S-lipoxygenase-4	Glycine max	101-113
6229601-1	1983	Cerulenin and dodecanoic acid prevented the synthesis and secretion of glucosyltransferase in non-proliferating cell suspensions of Streptococcus salivarius ATCC 25975 under conditions that also inhibited the incorporation of radioactively labelled acetate into the cell.	lauric acid	14-29	SSAL8618_RS07090	Streptococcus salivarius	71-90
7103935-1	1982	Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid).	lauric acid	114-129	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	41-57
7103935-1	1982	Purification and properties of a hepatic cytochrome P-450 relatively specific for the 12- and 11-hydroxylation of dodecanoic acid (lauric acid).	lauric acid	131-142	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	41-57
7103935-4	1982	One of these fractions (cytochrome P-450 fraction 1) was highly purified to a specific content of 17nmol of cytochrome P-450/mg of protein and the protein was active in a reconstituted enzyme system towards the 12- and 11-hydroxylation of the fatty acid, dodecanoic (lauric) acid, with preferential activity towards the 12-hydroxy metabolite.	lauric acid	255-279	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	24-40
7103935-4	1982	One of these fractions (cytochrome P-450 fraction 1) was highly purified to a specific content of 17nmol of cytochrome P-450/mg of protein and the protein was active in a reconstituted enzyme system towards the 12- and 11-hydroxylation of the fatty acid, dodecanoic (lauric) acid, with preferential activity towards the 12-hydroxy metabolite.	lauric acid	255-279	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	108-124
7103935-5	1982	This reconstituted activity was absolutely dependent on NADPH, NADPH-cytochrome P-450 reductase and cytochrome P-450, indicating the role of the mixed-function oxidase system in the metabolism of lauric acid.	lauric acid	196-207	cytochrome p450 oxidoreductase	Rattus norvegicus	63-95
7103935-5	1982	This reconstituted activity was absolutely dependent on NADPH, NADPH-cytochrome P-450 reductase and cytochrome P-450, indicating the role of the mixed-function oxidase system in the metabolism of lauric acid.	lauric acid	196-207	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	69-85
6788761-4	1981	Kinetic measurements established Ki = 1.5 X 10(-3) M for dodecanoic acid (lauric acid) inhibition of lipoxygenase when the substrate is linoleic acid (Km = 2.6 X 10(-5) M).	lauric acid	74-85	linoleate 9S-lipoxygenase-4	Glycine max	101-113
681331-0	1978	Purification and properties of cytochrome P-450 obtained from liver microsomes of untreated rats by lauric acid affinity chromatography.	lauric acid	100-111	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	31-47
6768332-2	1980	Portions of SAA and FAA antigens were chemically modified by conjugation with dodecanoic acid (SAADA and FAADA).	lauric acid	78-93	serum amyloid A protein	Bos taurus	12-15
7369609-2	1980	The SAA and FAA antigens were chemically modified by conjugation with dodecanoic acid (SAADA and FAADA).	lauric acid	70-85	serum amyloid A protein	Bos taurus	4-7
638175-6	1978	Addition of 5 mol lauric acid per mol albumin reduced the association constant of the progesterone complex by approx.	lauric acid	18-29	albumin	Homo sapiens	38-45
142634-1	1977	In vitro incubation of key glycolytic enzymes in supernatant fluids from rabbit kidney medulla with increasing concentrations of sodium laurate resulted in progressive inhibition of hexokinase, phosphofructokinase and pyruvate kinase.	lauric acid	129-143	hexokinase-2	Oryctolagus cuniculus	182-192
142634-1	1977	In vitro incubation of key glycolytic enzymes in supernatant fluids from rabbit kidney medulla with increasing concentrations of sodium laurate resulted in progressive inhibition of hexokinase, phosphofructokinase and pyruvate kinase.	lauric acid	129-143	ATP-dependent 6-phosphofructokinase, muscle type	Oryctolagus cuniculus	194-213
142634-1	1977	In vitro incubation of key glycolytic enzymes in supernatant fluids from rabbit kidney medulla with increasing concentrations of sodium laurate resulted in progressive inhibition of hexokinase, phosphofructokinase and pyruvate kinase.	lauric acid	129-143	pyruvate kinase PKLR	Oryctolagus cuniculus	218-233
1123546-1	1975	If bovine serum albumin (BSA) is covalently conjugated with dodecanoic acid, its ability to stimulate delayed-type hypersensitivity (DTH) is enhanced whereas its ability to stimulate antibody production is suppressed.	lauric acid	60-75	albumin	Homo sapiens	10-23
4129689-0	1974	The possible involvement of cytochrome b5 in the oxidation of lauric acid by microsomes from kidney cortex and liver of rats.	lauric acid	62-73	cytochrome b5 type A	Rattus norvegicus	28-41
33516753-8	2021	The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization.	lauric acid	17-31	lipoprotein lipase	Homo sapiens	185-188
33516753-5	2021	This paper describes the identification of a key excipient, sodium laurate, which can solubilize LPL in an isotonic environment without heparin or concentrated glycerol.	lauric acid	60-74	lipoprotein lipase	Homo sapiens	97-100
33516753-6	2021	A follow-up multi-variant study was performed to identify the effect of sodium laurate and its interaction with sodium chloride on the solubility and processing conditions of LPL.	lauric acid	72-86	lipoprotein lipase	Homo sapiens	175-178
33516753-7	2021	The LPL concentration (up to 14 mg/mL) achievable in pharmaceutically relevant and salt-free conditions was identified to be closely correlated to the concentration of sodium laurate, which was co-concentrated with LPL.	lauric acid	168-182	lipoprotein lipase	Homo sapiens	4-7
33516753-7	2021	The LPL concentration (up to 14 mg/mL) achievable in pharmaceutically relevant and salt-free conditions was identified to be closely correlated to the concentration of sodium laurate, which was co-concentrated with LPL.	lauric acid	168-182	lipoprotein lipase	Homo sapiens	215-218
33516753-8	2021	The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization.	lauric acid	17-31	lipoprotein lipase	Homo sapiens	55-58
33516753-8	2021	The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization.	lauric acid	17-31	lipoprotein lipase	Homo sapiens	185-188
33516753-8	2021	The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization.	lauric acid	192-206	lipoprotein lipase	Homo sapiens	55-58
33516753-8	2021	The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization.	lauric acid	192-206	lipoprotein lipase	Homo sapiens	185-188
33516753-8	2021	The results that sodium laurate increases stability of LPL characterized by differential scanning calorimetry and UV absorbance spectra suggests that the mechanism of solubilization of LPL by sodium laurate is related to LPL structural stabilization.	lauric acid	192-206	lipoprotein lipase	Homo sapiens	185-188
33442057-9	2021	Correspondingly, depletion of WAPL in v-Abl-transformed lines activated both processes, further implicating loop extrusion in the locus contraction mechanism.	lauric acid	40-43	WAPL cohesin release factor	Mus musculus	30-34
33188836-0	2021	Lauric acid ameliorates lipopolysaccharide (LPS)-induced liver inflammation by mediating the TLR4/MyD88 pathway in Sprague Dawley (SD) rats.	lauric acid	0-11	toll-like receptor 4	Rattus norvegicus	93-97
33188836-0	2021	Lauric acid ameliorates lipopolysaccharide (LPS)-induced liver inflammation by mediating the TLR4/MyD88 pathway in Sprague Dawley (SD) rats.	lauric acid	0-11	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	98-103
33450224-3	2021	Mice lacking the peroxisomal bi-functional enzyme enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase (Ehhadh) and supplemented with the 12-carbon fatty acid lauric acid (C12) accumulate the toxic metabolite dodecanedioic acid (DDDA), which causes acute hepatocyte necrosis and liver failure.	lauric acid	158-169	enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase	Mus musculus	50-101
33259010-0	2020	Lauric acid alleviates insulin resistance by improving mitochondrial biogenesis in THP-1 macrophages.	lauric acid	0-11	insulin	Homo sapiens	23-30
33259010-0	2020	Lauric acid alleviates insulin resistance by improving mitochondrial biogenesis in THP-1 macrophages.	lauric acid	0-11	GLI family zinc finger 2	Homo sapiens	83-88
33259010-4	2020	This research objective was to uncover the effects of the lauric acid on glucose uptake, mitochondrial function and mitochondrial biogenesis in insulin-resistant macrophages.	lauric acid	58-69	insulin	Homo sapiens	144-151
33259010-6	2020	Glucose uptake assay, cellular ROS and ATP production assays, mitochondrial content and membrane potential assay were carried out to analyse the effects of lauric acid on insulin resistance and mitochondrial biogenesis in the macrophages.	lauric acid	156-167	insulin	Homo sapiens	171-178
33259010-9	2020	Interestingly, lauric acid treatment upregulated glucose uptake, GLUT-1 and GLUT-3 expressions.	lauric acid	15-26	solute carrier family 2 member 1	Homo sapiens	65-71
33351113-5	2020	Moreover, knockout of p16 and p21 genes reduced both BCR-ABL-induced abnormal megakaryopoiesis and the maintenance of CML cell leukemogenic capacity, as evidenced by attenuated leukemogenic capacity at secondary transplantation.	lauric acid	57-60	cyclin dependent kinase inhibitor 2A	Mus musculus	22-25
33351113-5	2020	Moreover, knockout of p16 and p21 genes reduced both BCR-ABL-induced abnormal megakaryopoiesis and the maintenance of CML cell leukemogenic capacity, as evidenced by attenuated leukemogenic capacity at secondary transplantation.	lauric acid	57-60	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	30-33
32969559-11	2020	In contrast, combined oral administration of LAA and glucose recovered myocardial atrophy and MYL1 to levels observed in the control without increase in the cancer weight.	lauric acid	45-48	myosin, light polypeptide 1	Mus musculus	94-98
33259010-9	2020	Interestingly, lauric acid treatment upregulated glucose uptake, GLUT-1 and GLUT-3 expressions.	lauric acid	15-26	solute carrier family 2 member 3	Homo sapiens	76-82
33259010-11	2020	We show here that lauric acid has the potential to improve insulin sensitivity and mitochondrial dysregulation in insulin-resistant macrophages.	lauric acid	18-29	insulin	Homo sapiens	59-66
33259010-11	2020	We show here that lauric acid has the potential to improve insulin sensitivity and mitochondrial dysregulation in insulin-resistant macrophages.	lauric acid	18-29	insulin	Homo sapiens	114-121